- Author(s): Wolf, Ronni
- Matz, Hagit
- Orion, Edith
- Tuzun, Binnur
- Tuzun, Yalcin
- et al.
Published Web Locationhttps://doi.org/10.5070/D330m4b5kr
1. The Dermatology Unit, Kaplan Medical Center, Rechovot, Israel, 2. The Department of Dermatology, Trakya University, Medical
Faculty, Edrine, Turkey, 3. The University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Ronni Wolf1, Hagit Matz1, Edith Orion1, Binnur Tuzun2, Yalcin Tuzun3
Dermatololgy Online Journal 8(1): 2
Dapsone (4,4'-diaminodiphenylsulfone, DDS) was synthesized a century ago and continues to be a powerful therapeutic tool in many skin diseases. We have tried to retrieve and present the available knowledge and relevant information on this old but still very useful drug with the hope of encouraging and guiding practicing dermatologists to adapt it for various indications. Our objective is to familiarize the clinician with how this agent works, in what disease states it is effective, how to administer it, what adverse effects may occur, and how to monitor the patient receiving this drug.
Adapted from R. Wolf et al. "Dapsone: unapproved uses or indications" Clinics in Dermatology Vol. 18, January/February 2000, pp. 37-53.
"Because the newer methods of treatment are good, it does not follow that the old ones were bad: for if our honorable and worshipful ancestors had not recovered from their ailments, you and I would not be here today." [Confucius]
The unprecedented advances in immunology, molecular biology, and genetics over the last decade have created exciting opportunities and brought about the introduction of promising new drugs to ameliorate and even therapeutically cure many challenging skin diseases. Many of the new and innovative therapeutic devices and drugs are, however, produced by companies motivated largely by commercial interests. The physician of the third millennium is thus under constant pressure from both the pharmaceutical industry, and his/her patients to use and prescribe new (and usually expensive) drugs, while some older, no longer patented ones remain neglected "orphans" simply because they are no longer profitable or cost-effective for the pharmaceutical industry.
Dapsone has been the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy since it became available in the 1940s. [1,2,3,4] As an anti-infective agent, it is also used for treating malaria [5,6] and, recently, for Pneumocystic carinii pneumonia in AIDS patients. [7,8,9] Though dapsone's usefulness in these diseases is unquestioned, this chapter will mainly be devoted to the use of dapsone in non-infectious diseases.
Since the early 1950s, dapsone was recognized as being uniquely effective against a number of non-infectious inflammatory diseases, of which dermatitis herpetiformis is the best known. [10,11,12,13] The response of this disease to the drug is so dramatic (the pruritus is relieved within 48-72h) that it has even been considered as being a diagnostic indicator. [14,15,16] A considerable number of other inflammatory as well as bullous diseases have been shown to respond in varying degrees to dapsone, although the drug is not approved for them all. Today, dermatologists are much more aware of and interested in the anti-inflammatory immunosuppressive effects of the drug than in the antibacterial and antibiotic properties.
Dapsone was synthesized in 1908 by Fromm and Wittmann.  The discovery was not based on the search for a solution of a therapeutic problem but represented an achievement in the field of chemistry aimed at identifying a molecule for producing azo dyes.
Unrelated to Fromm and Wittmann's discovery, intensive efforts were being made at that time to combat bacterial infections by means of chemotherapy and many sulfonamide compounds were tested. In 1933, the first effective sulfonamide compound was submitted to clinical trials and it was put on the market as Prontosil in 1935. [18,19] This represented the great achievement of Gerhard Domagk who discovered that certain sulfonamides that had been developed by the chemists with whom he collaborated, Drs. Klarer and Mietzsch, showed antibacterial potential. In 1939, Domagk received the Nobel Prize for medicine and physiology for the "Discovery of the antibacterial effect of Prontosil", but was not permitted to accept it by the National Socialists of prewar Germany. In December 1949, he was awarded the diploma and the medal: "Professor Domagk. It has become clear during the eight years that have passed since it was decided to award you the Nobel Prize that the sulphonamides have introduced a new era in the treatment of infectious disease." An extensive search for chemically similar substances and for their anti-infective effects on various diseases soon followed.
Although dapsone was synthesized at the turn of the century, long before the synthesis of the sulfonamides, its anti-bacterial effects were not investigated until the late 30s. Two research groups, Buttle et al.  in England and Fourneau et al.  in France were the first to return to experimenting with the drug and investigating its chemotherapeutic effects. Since 1937, sulfones had been found to suppress the growth of various pathogenic bacteria, such as Streptococci, Staphylococci, Gonococci, Pneumococci, Mycobacteria leprae and tuberculosis, and others. [1,22,23] However, the observed beneficial effects of killing bacteria in experimentally induced infections of mice seemed to be associated with unacceptably toxic side effects. The sulfones were soon considered too toxic for humans and of no value in the treatment of human infections. [1,24] There is now no doubt that the negative side effects of dapsone had resulted from the excessive dosage which was administered at that time, compared to the amounts being used today. In any event, experimental studies on dapsone and related sulfones were not abandoned, and in the early 1940s these drugs gained worldwide recognition for treating leprosy and other infectious diseases. [25,26,27,28]
In 1950, a great discovery that prepared the way for sulfones in dermatology was made serendipitously, because of an incorrect assumption. Two researchers from Portugal assumed that dermatitis herpetiformis of Duhring was an infectious disease. When they examined the effects of various sulfones on this disease they found excellent results. Other investigators soon confirmed the efficacy of the compound for this disease.  The introduction of penicillin as well as of many other efficient antibiotics has considerably altered the uses of dapsone in medicine, and its main applications are now in the treatment of non-infectious inflammatory, autoimmune, and bullous diseases.
Pharmacology of dapsone
Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Peak concentrations of dapsone in plasma are reached within 2 to 8 hours after administration. The mean half-life of elimination is about 20 to 30 hours. Twenty-four hours after oral ingestion of 100 mg, plasma concentrations range from 0.4 to 1.2 µg/ml, and a dose of 100 mg per day produces steady-state plasma concentrations of free dapsone of 2 to 6 µmol/L. [31,32] About 70% of the drug is bound to plasma protein.
Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.
After absorption from the gastrointestinal tract, dapsone is transported through the portal circulation to the liver, where it is metabolized by two distinct routes, N-acetylation and N-hydroxylation. (Figure 1) Dapsone toxicity, in particular methemoglobin formation, is putatively initiated by N-oxidation, resulting in the formation of a hydroxylamine metabolite by cytochrome P450.  A recent study showed that the P450 accounting for the majority of dapsone hydroxylamine formation in vivo is the CYP2E1. To a lesser extent, CYP2C also metabolizes dapsone. A single dose of disulfiram, a slowly reversing inhibitor of CYP2E1 in vivo, inhibited dapsone hydroxylamine formation clearance by 73%, and inhibited methemoglobin formation by 78% in a group of healthy volunteers. Dapsone-induced methemoglobin formation in healthy volunteers was also diminished by 61% following the administration of cimetidine, a relatively non-selective P450 inhibitor. The authors speculated that the treatment-limiting toxicities of dapsone might be diminished by co-administration of a suitable inhibitor of hydroxylamine formation, as evidenced in their study.
The fate of the toxic metabolite of dapsone, dapsone hydroxylamine, has been studied in the human red cell. The parent amine was produced from dapsone hydroxylamine during methemoglobin formation in the red cells, and there was a linear relationship between hydroxylamine-dependent methemoglobin formation and conversion of hydroxylamine to dapsone. The authors suggested that a cycle exists between the hepatic oxidation of dapsone to its hydroxylamine form and reduction to amine within the red cell, a process, which might lead to re-oxidation by the hepatic cytochrome P450. They speculated that this process might contribute to the persistence of the drug in vivo. 
Clinical uses in various cutaneous diseases (in alphabetical order)
The usefulness of dapsone has long been recognized in the treatment of severe, nodulocystic, inflammatory acne. Although it is mentioned in most of the textbooks and review articles as one of the many therapeutic options for treating acne, the evidence to support this has been inadequate and largely anecdotal or based on single case reports. Four studies have attempted to evaluate its efficacy.
In a double-blind trial comparing dapsone and placebo, a significant number of cases, which responded favorably, were observed only at the 5% level. The author concluded that the results achieved with dapsone were inferior to those normally seen with broad-spectrum antibiotic therapy.
In an uncontrolled study of 484 cases of acne of varying severity treated with dapsone 300 mg weekly, a dramatic response was found in patients with Grade IV disease: there was a remission of 80% of the lesions at the end of a 3-month treatment period.  The response of patients with mild and moderate forms of acne was minimal, not reaching that of oral tetracycline. Similar results were obtained in another study on eleven acne patients: nine of them improved within 8 weeks of commencing dapsone 300 mg weekly.  Unfortunately, both studies were uncontrolled and the authors did not indicate how their clinical assessments had been made, thus their results are difficult to evaluate.
In a comparison of daily doses of 100 mg dapsone with 40 mg 13-cis retinoic acid in forty male patients with nodular/cystic acne, only a marginal clinical benefit was observed with dapsone, which also produced no significant effect either on the sebum excretion rate or on skin surface microflora. Dapsone was obviously inferior to retinoic acid. 
The introduction of isotretinoin in the treatment of acne in the early 1980s has brought a significant change in our approach to the treatment of this disease.  Because of its extraordinary efficacy, it became the drug of choice for severe cases of acne, replacing all other therapies, including dapsone.
There is one exception, however. The role of isotretinoin in the treatment of acne fulminans or acne with musculoskeletal symptoms is still uncertain. There are at least 15 reported cases of acne fulminans induced or precipitated by isotretinoin. [50,51,52,53,54,55] The few contrasting reports on the successful treatment of acne fulminans with retinoids are not sufficient to support the use of retinoids in acne fulminans and do not justify a change in our therapeutic approach to this disease.[56,57,58] Thus, until more data are available, systemic steroids [59,60] and dapsone [55,61] still remain the two recommended and safest drugs for this disease.
According to a recent review, dapsone is an effective oral therapy for persistent aphthae and cutaneous manifestations of moderate cases of Behcet's disease. It was not recommended for severe mucocutaneous or ocular and systemic manifestations. Dapsone is mentioned as a therapeutic option for Behcet's disease in many other review articles and textbooks as well.
It is quite surprising that the scientific basis for this therapeutic option consists of, in fact, only very few reported studies and case reports. All seven affected male patients who had been treated with dapsone 100 mg daily showed a noticeable symptomatic improvement in one study. The uro-genital ulcers, erythema nodosum, and boil-like lesions cleared up within a few weeks. The condition of two patients flared up upon stopping dapsone and treatment was satisfactorily resumed. All the patients had suppression of their pathergic reaction to a deep needle-prick.  One patient had a similar improvement: the flare-up of his lesions, which followed discontinuation of the drug, resolved when dapsone was readministered.  In a report of five cases in South Africa, four of them responded well to the administration of dapsone.  In a report from the United States of twenty-five patients who had prominent mucocutaneous involvement, all four who were treated with dapsone demonstrated a 50% decrease in the size, frequency, and duration of their mucocutaneous lesions. 
The value of dapsone for the treatment of Behcet's disease needs to be further confirmed by carefully controlled trials before it can become an established drug for treating this disease.
Bullous pemphigoid is not generally considered to be a sulfa-responsive dermatosis. In his two monographs on pemphigus and bullous pemphigoid. [67,68] Lever stated that the sulfones are of little or no value for treating these conditions. Indeed, a bullous dermatosis responsive to sulfas and sulfones was once considered by some to be diagnostic of dermatitis herpetiformis. [69,70,71] However, in 1953, when sulfapyridine was used to treat 17 of 38 patients with bullous pemphigoid, the condition was controlled in four, it improved in seven and it was unchanged or aggravated in six.  Too little has been written regarding the use of sulfones for the treatment of bullous pemphigoid to reach any firm conclusions.
In 1972, Honeyman et al. described five patients with clinical histopathologic and immunofluorescent criteria for both dermatitis herpetiformis and bullous pemphigoid who had a good response to dapsone. 
A report in 1976 on 3 patients with classical bullous pemphigoid noted that they responded dramatically to dapsone and showed control of the disease within 2 weeks . The same group, one year later reported three additional proven cases of bullous pemphigoid in childhood, which responded to dapsone.  These studies supported previous case reports by others who also found dapsone effective in the treatment of bullous pemphigoid.[76,77,78]
Of 84 patients with bullous pemphigoid treated in the Mayo Clinic between 1968 and 1975, 41 were given a trial of sulfapyridine or dapsone. Only six showed a significant response of whom five were controlled completely. [79,80]
Other authors were more enthusiastic about the benefits of dapsone in bullous pemphigoid. In one open study, 18 patients with proven bullous pemphigoid were treated with a trial of the drug. Eight patients (44%) had a complete response and six (33%) had a partial one.  The authors concluded that a trial of a sulphone drug is warranted in bullous pemphigoid either as an initial treatment or in the treatment of relapse, particularly when there is a contraindication to the use of corticosteroids.
Another study evaluated the efficacy of dapsone as adjuvant therapy.  Thirteen patients with recurrent, severe, widespread, recalcitrant bullous pemphigoid who had initially responded to prednisone and azathioprine continued to have flare-ups of the disease while still on high doses of the drugs. The addition of dapsone as an adjuvant to the treatment helped to produce a complete clinical remission in 12 patients (92%), and enabled the tapering of prednisone. The authors concluded that the addition of dapsone to the existing regime of corticosteroid immunosuppressive drugs might be beneficial.
These and other reports [83,84,85] bring us to the same conclusion that Lever expressed more than thirty years ago, namely, that sulfones might be of value to some patients with bullous pemphigoid, but the mainstay of therapy for this disease are the corticosteroids. Dapsone can be used in patients in whom systemic steroids are ineffective, or are contraindicated, or have to be discontinued because of side effects.
This is also the conclusion of a retrospective study of 36 patients with bullous pemphigoid who were treated with dapsone alone (n=15), dapsone with topical corticosteroids (n=19) or dapsone and systemic steroids (n=2).  In this study the efficacy of dapsone appeared to be limited (a response rate of 44%, mainly in patients also treated with topical steroids), not far from that recorded by other investigators in patients receiving potent topical steroids alone. 
Cicatricial pemphigoid, previously termed benign mucosal pemphigoid, is actually not so "benign" but a rather chronic progressive disease that seldom goes into complete remission spontaneously, and one that scars mucous membranes and might cause severe complications. Therapy of cicatricial pemphigoid depends on the extent of the disease, its severity and the organs involved. In limited cases, topical and intralesional treatment will suffice, however, systemic therapy is mandatory in patients with extensive oral or ocular involvement. Dapsone is certainly one of the drugs to be considered in the treatment of this disease, which is not highly responsive to steroids. There are several published studies that have shown the therapeutic efficacy of dapsone.
Twenty-four patients with cicatricial pemphigoid were treated with dapsone. Twenty (83.3%) had partial or complete control of the inflammatory activity. The use of dapsone was discontinued in two patients because it failed to control their disease and in four patients because of drug-related side effects. The authors concluded that cicatricial pemphigoid might be added to the list of dapsone-responsive dermatoses. 
The records of 105 patients treated with three different chemotherapeutic agents for ocular cicatricial pemphigoid were reviewed to compare long-term efficacies and side effects of different drug regimens.  As the initial agent, dapsone failed to control the disease in 2% of patients, compared with an 8% failure in patients taking cyclophosphamide and 9% in those on azathioprine.
Oral dapsone was used to treat five patients who presented in the acute inflammatory phase of ocular pemphigoid. In all cases, it was the inflammatory rather than the cicatricial features which responded to treatment. The clinical response was obtained after 1-4 weeks and could be maintained on a dose of between 50 mg on alternate days and 100 mg/day. All cases required continuation of the therapy in order for it to remain effective. 
In a study of long-term outcome and follow-up (average 4 years) of 104 patients with ocular cicatricial pemphigoid, dapsone was used as the first-line agent with azathioprine or cyclophosphamide being added in cases of unsatisfactory response.  Slightly more than one-third of the patients responded to therapy and remained free of inflammation following cessation of therapy. Another one-third was free of disease activity but needed continuation of therapy. Nearly one-third of the patients responded only partially to treatment.
The response to sulphapyridine 500 mg twice daily was evaluated in a prospective, single-armed, unmasked clinical trial of 20 consecutive patients with ocular cicatricial pemphigoid. Sulphapyridine was clinically effective in 50% of patients with moderately marked inflammation. The authors suggested that it might be a good alternative to dapsone. 
A recent study characterized a subset of cicatricial pemphigoid in which the disease was limited to only the oral cavity ("oral pemphigoid"). Twenty-nine random patients with this form of the disease were studied. The patients with limited or minimal disease received only local therapy. In the 14 patients (48%) with extensive or severe disease, systemic therapy was added, while dapsone was the only treatment used in seven patients. Patients with severe disease who were treated with dapsone followed a clinical course similar to that of patients with minimal disease, which indicated that dapsone was beneficial and that it did cause an alteration in their clinical course.
In conclusion, there is general agreement among experts that dapsone is an effective treatment for cicatricial pemphigoid in the majority of patients and that it should be used as the first-line drug in those patients for whom local therapy is unsuitable. [94,95,96,97,98,99,100] For severe, rapidly progressive forms of the disease with involvement of the eye, esophagus, or larynx, aggressive systemic therapy with immunosuppressive agents, such as cyclophosphamide, is warranted.
Epidermolysis bullosa acquisita (EBA)
The rarity of this condition has precluded proper therapeutic trials. The disease is characterized by resistance to usual treatment modalities, such as high doses of systemic steroids, azathioprine, methotrexate and cyclophosphamide, especially in its classical, mechanobullous form. The bullous pemphigoid variant of the disease is somewhat more responsive to treatment with the above-mentioned agents.
Dapsone alone or in combination with steroids is considered one of the standard treatments for this disease. Moreover, this combination appears to be the most effective one for pediatric EBA. Remission is achieved within a few days to a few weeks, and the use of prednisone can generally be stopped within one year. Treatment with dapsone alone is sometimes continued for a few months or years. The prognosis in children seems generally better than in adults. [101,102,103,104,105,106,107,108,109,110,111,112] Indeed, treatment of EBA in adults is inconsistent and less promising. There are many reports on failures following a combination treatment of dapsone and prednisone. [113,114,115,116] It should be noted, however, that the literature reflects an abnormally and disproportionately high incidence of treatment failures because of the tendency to report unusual and innovative treatments, as compared to the prednisone/dapsone combination, which is a conventional and standard therapy for EBA. It follows that many reports on new treatments, such as extracorporal photochemotherapy, cyclosporin A, plasma exchange, intravenous immunoglobulins, colchicine, and others, were started in patients who were refractory to dapsone/prednisone therapy and thus the high number of reports on resistance to dapsone.
Erythema elevatum diutinum
Erythema elevatum diutinum is a rare, chronic form of cutaneous vasculitis. The disease is so rare that one large tertiary referral center with special expertise in cutaneous vasculitis has seen only 13 cases over a period 60 years.  Probably because of the tendency to publish rare conditions, there are more reports on the effectiveness of dapsone in this disease than there are on other forms of leukocytoclastic (necrotizing) vasculitis. Many case reports [118,119,120,121,122,123,124,125,126,127] and series of patients [128,129,130,131] have indicated the regularity with which a dramatic response is obtained when patients with erythema elevatum diutinum are treated with dapsone. The prompt recurrence of skin lesions and systemic symptoms after sulfone withdrawal is evidence of the suppressive but not curative effect of sulfones in this disease. It should be noted that the disease as well as the individual lesions are chronic and persistent ("diutinum" means persistent) and usually show no tendency for spontaneous remissions.  Therefore, the dramatic clearing of lesions in treated patients could be attributed with confidence to therapeutic efficacy.
All early and most late lesions of erythema elevatum diutinum show a leukocytoclastic angiitis associated with a dense, dermal infliltrate composed primarily of neutrophils and occasionally of monocytes. Some late lesions show fibrohistiocytic proliferation with areas of granulation tissue and fibrotic replacement of normal dermal structure.  These late fibrotic nodules are not responsive to dapsone. 
Regression of Kaposi's sarcoma in a 38-year-old homosexual man with AIDS after treatment with dapsone was reported in 1984.  The patient was treated exclusively with dapsone 100 mg daily, and two Kaposi plaques had regressed and turned into brownish atrophic scars after 6 weeks of therapy. The whole area was then excised and no histological features of Kaposi's sarcoma were found.
This observation encouraged the same group to study the effect of dapsone in six patients with Kaposi's sarcoma of the skin.  The patients, four males and two females, with biopsy-proven plaque and/or nodular Kaposi's sarcoma of the skin for 3-10 years without clinical signs of systemic spreading, were given 100 mg dapsone daily for a period of four months. The treatment resulted in clinical improvement in four of the six patients. These four patients had presented with plaques of Kaposi's sarcoma, and during the treatment, all the plaques gradually regressed into brownish pigmented atrophic scars in three, while the plaque became less infiltrated in the fourth patient. No clinical improvement was found in the other two patients, of whom one had only nodules and the other both nodules and plaques. Three of the patients had complete histological regression of the tumor.
One year later, another group of authors tried to confirm these observations in a pilot study of twelve homosexual male volunteers with biopsy-proven Kaposi's sarcoma skin lesions.  These patients, who were receiving no other medications, were put on dapsone 100 mg daily. Therapy was discontinued early in three patients because of side effects. All of the nine men who completed at least a 6-week course of dapsone continued to have new lesions develop throughout the treatment period. The original lesions did not change or increase, and no lesion resolved or decreased in size. The obvious conclusion of the authors was that, in disagreement with previous studies, dapsone is totally ineffective in AIDS patients with Kaposi's sarcoma.
In another study, the authors described the clinical and histological changes in well-established classic Kaposi's sarcoma lesions during 2 years of therapy with dapsone. Both patients showed a vast improvement in their symptoms although the clinical examination showed no significant modifications of the lesions. Histology did show a striking reduction in the spindle-cell component and an increase in the number of mature vessels.
A more recent study described two patients with classical, non-HIV-related Kaposi's sarcoma who were successfully treated with dapsone, further confirming the contention that dapsone might favorably modify the lesions of Kaposi's sarcoma. 
This form of therapy clearly requires additional randomized trials with uniform staging and evaluation criteria before its use in Kaposi's sarcoma can be recommended. In view of the current data and our own disappointing experience (unpublished observations), it seems overly optimistic to assume that dapsone will be the panacea for Kaposi's sarcoma.
Linear IgA bullous dermatosis
Linear IgA bullous disease is an acquired, autoimmune subepidermal blistering disorder characterized by linear deposition of IgA at the basement membrane zone. It has a clinical presentation and a histopathologic appearance similar to that of both dermatitis herpetiformis and bullous pemphigoid. Until 1979 when it was first described and defined as a disease entity by Chorzelski et al. , some authors considered it as a variant of dermatitis herperiformis, some as bullous pemphigoid [73,138,139,140,141,142] and others as an intermediate form between the two diseases. 
The most important difference between dermatitis herpetiformis with granular IgA deposits and linear IgA bullous disease is the absence in the latter of nontropical sprue [144,145]. A gluten-free diet, which is helpful in dermatitis herpetiformis if strictly observed, is of no benefit in cases of linear IgA bullous dermatosis. [146,147,148]
Considering the similarities between dermatitis herpetiformis and linear IgA bullous dermatosis, it is not surprising that both diseases respond to the same therapy, dapsone. Indeed, it is generally accepted that dapsone is the drug of choice in linear IgA bullous dermatosis. Most patients will respond to 100-150 mg dapsone with clearing of the skin lesions. The dosage is then gradually lowered to a maintenance level of 50 mg every second day. Some patients (the minority) who improve only with very high doses of dapsone can be controlled with a combination of dapsone and small doses of corticosteroids. [137,149,150,151]
Linear IgA bullous disease of childhood (chronic bullous disease of childhood)
Most authors currently consider chronic bullous dermatosis of childhood and linear IgA bullous dermatosis of adults as being the same disease; hence the proposed name, linear bullous disease of adults and childhood. [148,154,155,156,157] The majority of patients with linear IgA bullous dermatosis of childhood will go into remission usually within 2 to 4 years, and almost always before puberty. [148,158]
As in the adult variant of the disease, treatment with sulfapyridine or dapsone usually results in excellent control of the disease. [158,159,160,161,162,163] The response is rapid, usually within 72 hours. In patients who do not respond adequately, prednisone in small doses may be added as adjunctive therapy. [150,159]
Lupus erythematosus (LE)
Patients with cutaneous discoid lupus erythematosus (DLE) or subacute cutaneous LE (SCLE) generally have a favorable prognosis and can be managed with safe, yet effective, therapy. Sun protection and sunscreens (with both UVA and UVB protection) are the most important measures. Topical steroids, with or without occlusion, and intralesional steroid injections are effective local therapies. Systemic therapy with antimalarials is usually effective for patients who do not respond to topical regimens. Dapsone is not considered a first-line therapy. However, under certain circumstances (e.g., when "standard" therapy fails, is contraindicated, or when dealing with special forms of cutaneous lesions) it may be effective and is worth trying.
Urticarial lesions with underlying vasculitis seem to be quite common in systemic lupus erythematosus (SLE).  In 1978, a dramatic improvement of such lesions in a female patient with SLE was reported , a therapeutic effect of dapsone that could be reproduced in several other cases. [166,167]
Thrombocytopenia is a serious problem in patients with SLE. It is sometimes refractory to steroid therapy and splenectomy, which is the alternative recommended treatment. There are at least two reported cases in which dapsone corrected the thrombocytopenia in these patients. [174,175]
Although dapsone use has led to an improvement in some patients with DLE, the level of benefit was too small to suggest routine use of this therapy. Nearly one-fourth of 37 patients with DLE had an excellent resopnse to dapsone; another fourth showed some effect; while no response was seen in 52% of the patients.  Of the patients who had earlier been treated with hydroxychloroquine, 76% had an excellent response to the treatment. Six patients (18%) stopped dapsone treatment because of side effects. The authors concluded that hydroxychloroquine and not dapsone remains the drug of choice when systemic therapy is needed. These results are in agreement with previous studies by the same group and by others. [177,178]
Mycetoma is a localized, chronic infection by various species of fungi or actinomyces (which occur as saprophytes in soil or on vegetable matter). These infections frequently result in severe damage to skin, subcutaneous tissues and bones of the feet, hands and other parts of the body.
The disease (a clinical and not an etiological entity) occurs most commonly in tropical and subtropical climates, usually among laborers who work barefoot and observe poor hygiene.
The course of the disease is prolonged, and treatment has been notoriously unsatisfactory. The combination of dapsone with other antibiotic and antifungal drugs has been reported to give favorable results. [179,180,181,182,183,184,185,186,187]
In 1972, a new form of panniculitis was described, namely, lobular panniculitis associated with alpha-1-antitrypsin deficiency.  It is inherited as the ZZ phenotype, and occurs in about one in 2500 individuals This form of panniculitis probably accounts for about 14% of all cases of panniculitis, although only a few have been reported thus far, probably because of lack of awareness and underdiagnosis. 
The most direct approach to therapy of alpha-1-antitrypsin deficiency-associated panniculitis may be alpha-1-proteinase inhibitor replacement, and indeed, there are several reports on good responses to this form of therapy.  There are, however, many more reports of good responses to dapsone. [190,191,192,193,194,195,196] Dapsone is considered by most, if not all, of the authors as the first drug of choice for this distinctive and unique form of panniculitis.
Oral steroids are the cornerstone and primary agent for treatment of pemphigus. Before the introduction of adequate treatment with steroids the prognosis of pemphigus was very poor, with a mortality rate of up to 90%. With the introduction of systemic steroids in the 1950s the picture has changed dramatically and the mortality rate has dropped sharply. However, steroid therapy has created other problems, including rates of mortality of about 25%. 
Although there are some reports of the effectiveness of dapsone in the treatment of pemphigus vulgaris [198,199,200], mostly in conjunction with steroids [201,202,203], and in pemphigus foliaceous [204,205,206,207], pemphigus is not generally considered to be a dapsone-responsive dermatosis and we do not recommend its use in this disease.
Interestingly, in two in vitro experiments dapsone did not inhibit acantholysis of human epidermal cells cultured with pemphigus antibody , nor did it reduce the production of plasminogen activator in contrast to steroids.
Pemphigus herpetiformis is recognized as a distinct variant of pemphigus. This disease was originally named and the diagnostic criteria were described by Jablonska et al. in 1975. However, patients with similar clinical phenotypes were described as early as 1955 by Floden and Gentale under the heading "dermatitis herpetiformis with acantholysis". Since then more than 40 additional cases have been presented in the literature. [212,213,214,215]
Pemphigus herpetiformis combines the clinical features of dermatitis herpetiformis with the immunologic and histologic features of pemphigus.
Dapsone is the drug of first choice for the treatment of pemphigus herpetiformis with doses ranging from 100 to 300 mg daily. [150,212,213,216,217] The response to dapsone is as dramatic in some (but not all) patients as in dermatitis herpetiformis. Cases with low or negative antibody titers or those demonstrating eosinophilic spongiosis are the best candidates for this therapy. Dapsone may be given as monotherapy or in combination with systemic corticosteroids and immunosuppressants. 
IgA pemphigus is a newly characterized group of autoimmune, intraepidermal blistering diseases presenting with a vesiculopustular eruption, neutrophil infiltration, acantholysis, and in vivo bound and cirdulating IgA autoantibodies that target cell surface components of the epidermis. [219,220,221] There are two distinct types of IgA pemphigus: the subcorneal pustular dermatosis (SPD) type and the intraepidermal neutrophilic (IEN) type. [222,223] Patients with both types of IgA pemphigus clinically present with flaccid vesicles or pustules or both on erythematous or normal skin. Pruritus is a significant symptom that may interfere with the patient's daily activities.
Dapsone has proved to be the drug of choice in the treatment of IgA pemphigus. [219,220,221,224,225] Therapeutic alternatives in cases in which dapsone is not well tolerated, or its effects are insufficient or transient, include systemic or topical steroids, PUVA, retinoids and various combinations of these. Though all of these are second-line treatments, while dapsone remains the drug of choice.
Although the belief that pyoderma gangrenosum was an infectious condition has fallen into disfavor, certain antimicrobial agents have been tried and even found to be successful in treating the disease. Their mode of action is clearly not related to their antibacterial effect, but rather to an anti-inflammatory, immunomodulating effect.
Sulfa drugs have been one of the most commonly used agents in the treatment of pyoderma gangrenosum. Sulfasalazine, a sulfonamide whose main use is for treating inflammatory bowel disease, was the first sulfa drug to be tried for alleviating pyoderma gangrenosum. It was initially reported in 1957 to be beneficial in the treatment of nine of twelve patients with pyoderma gangrenosum and proved to be effective even in patients without underlying inflammatory bowel disease. 
Because sulfasalazine is metabolized in the gut to sulfapyridine and 5 aminosalicylate, several researchers tried sulfapyridine alone and reported success in several cases of pyoderma gangrenosum. [227,228,229,230] In some of them, the response to sulfapyridine was seen after failure with sulfasalazine, possibly because of the higher blood levels that can be achieved with the former.
The first report of the successful treatment of pyoderma gangrenosum with a derivative of dapsone appeared in 1962 with a report of four patients that responded favorably to this therapy.
Subsequently, several other authors reported on the successful treatment of pyoderma gangrenosum with dapsone alone [231,232] and in combination with oral [233,234], intravenous , or intralesional steroids. 
All told, there are only a very few reports on the efficacy of dapsone in the treatment of pyoderma gangrenosum, and all of them describe single cases or limited case series (i.e., a maximum of 4 patients). This may be due to the rarity of the disease, estimated at 3 cases per 1 million populations per year. However, we suspect that the real reason is probably the unconvincing outcomes of this therapy combined with the tendency of investigators to report mostly positive results. Although currently available treatment for pyoderma gangrenosum is far from satisfactory, we cannot recommend the use of dapsone until more data on this therapy are available.
Malignant pyoderma, which was described as a new disease entity in 1968 is now considered a subtype of pyoderma gangrenosum [237,238]. Generally, malignant pyoderma responds well to corticosteroid therapy, but relapses occur when the dose is gradually lowered. Dapsone can be given in combination with steroids and in some rare cases, it was reported to be effective even when steroids failed. [236,239]
First described in 1923, relapsing polychondritis is an uncommon disease of possible autoimmune etiology manifested by recurrent episodes of progressive inflammation and destruction of cartilages. This multisystem disease can have severe consequences: it can cause facial deformities as a result of destruction of the nose and ear cartilages; it can lead to blindness; and it was shown to have a fatal outcome in as many as one-fourth of affected patients.  Until 1976, the recommended treatment was systemic steroids. Two articles, both appearing in 1976 and in the same issue of the Archives of Dermatology, described the effectiveness of dapsone in treating relapsing polychondritis. [242,243] Since then, several other reports confirmed the beneficial effects of dapsone in controlling the disease, [244,245,246,247,248,249,250,251,252] although the experience of other authors with dapsone alone or in combination with steroids was disappointing. [249,253,254,255,256,257]
The rarity of relapsing polychondritis, the diversity of its presentation, and the unpredictable recurrence rate are all factors that preclude randomized controlled therapeutic clinical trials, critical evaluation of the efficacy of dapsone and the establishment of a standardized therapeutic protocol. Although the ideal treatment for relapsing polychondritis has not yet been found, the available evidence indicates that dapsone and/or systemic corticosteroids are the most effective therapies, with neither showing significant advantage over the other.
Bites from spiders range in severity from a minor and negligible reaction to full-thickness skin necrosis and/or to severe systemic symptoms leading to death. Although most bites are not serious and resolve without any interventions, severe reactions require hospitalization and medication. The treatment of spider bites is varied and very controversial. The first documented case of cutaneous loxoscelism in North America was reported in 1929. It had been ineffectively treated with sedation, starch, and sodium bicarbonate. Current therapies for spider bites, such as corticosteroids (systemic or intralesional), antibiotics, antihistamines, surgical treatments, heparin, NSAIDs, and hyperbaric oxygen appear not to be much more effective in preventing necrosis and ulcers.
The fact that dapsone is an inhibitor of polymorphonuclear (PMN) leukocyte function, which had been proven effective in 'neutrophilic dermatoses', and that PMN leukocytes play a dominant role in spider bite-induced necrosis, led some investigators to attempt treating this condition with the drug.  In 1983, the first case was reported on the successful use of dapsone in the treatment of a documented bite from the brown recluse spider.  A 27-year-old man killed the spider immediately after it had bitten him on the leg. Forty-eight hours after the event, the lesion was tender, erythematous and indurated and there was evidence of early blister formation and incipient cutaneous necrosis. The patient was treated in the hospital with leg elevation, ice packs and dapsone 100 mg orally twice daily. By the second hospital day, the bitten area was pain free and there was a marked reduction in the erythema and induration. The lesion completely resolved during 14 days of dapsone therapy. This clinical trial was done after the authors had confirmed the effectiveness of dapsone in a guinea pig model of cutaneous loxoscelism.  Thirty guinea pigs pre-treated with oral dapsone (1.73 mg/g body weight) had a marked reduction in skin lesion size at 24 hours, compared with control guinea pigs, after having been injected intradermally with a partially purified brown recluse spider venom fraction.
Following this report, the effectiveness of dapsone on local and systemic symptoms of spider bites was evaluated in clinical and experimental studies.
The effect of three treatment methods, hyperbaric oxygen, dapsone and cyproheptadine, on the severity of skin lesions resulting from experimental Loxosceles envenomation in New Zealand white rabbits was determined in a randomized, blinded, controlled study. The three groups of animals did not differ significantly with respect to lesion size, ulcer size, or histopathologic ranking. The authors concluded, "Given the negative result in this study with adequate power to detect meaningful treatment benefits, we cannot recommend hyperbaric oxygen, dapsone, or cyproheptadine in the treatment of Loxosceles envenomation.."  Although their study involved the use of venom from Loxosceles deserta (not venom from the true brown recluse spider, L. reclusa) and new Zealand white rabbits (not humans), the results should raise second thoughts about such enthusiasm for using dapsone to treat spider bites.
Another animal study examined the effectiveness of dapsone or electric shock therapy vs. placebo on the size of lesions induced by intradermal injections of spider venom in guinea pigs. The dapsone therapy group demonstrated significantly less induration and necrosis (p<0.05) than that shown by the other groups at 72 hours after envenomation. The authors concluded that dapsone therapy was more effective than either electric shock or no therapy for brown recluse spider envenomation in their guinea pig model. 
The management of eyelid spider bites is particularly difficult.  Several treatment regimens of eyelid envenomation have been studied in a rabbit model.  The combination of dapsone and antivenom treatment comprised the optimal animal regimen, although it was not completely effective in eliminating microscopic necrosis. The authors also reported dramatic clinical improvement in the human inflammatory response with dapsone therapy and recommended immediate dapsone therapy combined with specific antivenom, if available, in humans.
Early surgical excision versus dapsone and delayed surgical excision were compared in a prospective study of 31 patients with brown recluse spider bites. Patients were matched for age, gender and lesion size. In 14 patients treated with immediate surgical excision, delayed wound healing (N=5) and unacceptable scarring (N=6) were common complications. Pre-treatment with dapsone reduced the incidence of wound complications, objectional scarring, and the need for surgical excision in one case of each (p<0.05). This study clearly demonstrated the benefits of the treatment with dapsone in terms of reducing surgical complications and improving significantly patients' outcomes. 
The same group of authors reported on their experience with 31 patients who had brown recluse spider bites of an upper extremity.  Their conclusions were similar to those of the previous study, namely, that there would be a high incidence of functional complications unless conservative wound management, dapsone, and antibiotics were administered.
The experience of the same group with 95 patients who were bitten by brown recluse spiders between 1983 and 1986 was described in another paper.  The patients were randomized into three treatment groups: dapsone, brown recluse spider antivenom, or combination therapy. In addition, all the patients were treated with erythromycin. Excluding two patients with very severe lesions, the wounds of patients in all the groups healed in an average of 20 days. No clear conclusions about the superiority of one form of therapy could be drawn from this study, nor from the comparison of the results with similar reported cases.
Clinical presentation and outcome were evaluated in 111 patients with suspected brown recluse spider bites and who were treated during a 30-month period.  Most wounds (59%) involved the leg. At the time of presentation, 81% had central discoloration and 37% had necrosis. Sixteen patients (14%) were systemically ill, and six (5%) were admitted to the hospital. Most (86%) were treated with antibiotics, and only 9% of the patients had received dapsone before presentation to the clinic. In this series, the long-term outcome after brown recluse spider bite was good compared to other reported series. Serious complications were rare, as was the need for skin grafting (only 3 patients). The authors' conclusion was that since the vast majority of bites heal with supportive care alone, aggressive medical therapy is not warranted.
In conclusion, several experimental studies and large clinical trials have shown the beneficial effect of dapsone in reducing the severity of local and systemic reactions to spider bites, decreasing complications and improving patients' outcome. Most of the cases of spider bites are mild and free of severe complications, and symptomatic therapy with rest, ice, compression and elevation is usually sufficient. If necrosis or systemic reactions occur, then most [268,269,270,271,272,273,274,275,276], although not all  authors recommend early treatment with oral dapsone.
Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)
This disorder was originally described in 1956 by Sneddon and Wilkinson, who differentiated it from other pustular and vesicular eruptions.  A sufficient number of patients (over 130 from 1965 when the first review appeared to the present) has been reported to establish the condition as a morphological entity separate and distinctive from other pustular and vesicular conditions.
Dapsone 50-100 mg daily is the treatment of choice for Sneddon-Wilkinson disease and, although the response is slower than that seen in dermatitis herpetiformis, the majority of patients obtain partial, if not complete, relief. Unlike dermatitis herpetiformis, treatment can often be stopped without relapse. [280,281,282]
A review of 29 patients with intraepidermal IgA deposits and with clinical and histological features of Sneddon-Wilkinson disease appeared in 1992.  Dapsone was the first line of therapy in 23 patients, and was judged as being effective, resulting in a dramatic and long-lasting improvement in 16 of these patients.
A condition that can very closely resemble subcorneal pustular dermatosis is pustular psoriasis. Most , although not all , authors agree that the failure of pustular psoriasis to respond to sulfones as opposed to subcorneal pustular dermatosis is one of the most reliable criterion to differentiate between these two diseases.
Urticarial vasculitis syndrome
Urticarial vasculitis syndrome is a distinct clinico-pathological entity characterized by purpuric, urticarial weals and histologically showing all the criteria of leukocytoclastic vasculitis. It represents a systemic disease that involves a number of organs, particularly the joints, lung and kidneys. In most of the cases, it is associated with or is a result of an underlying disease, such as a drug reaction, connective tissue disorder, infection or malignancy. In these cases, the primary therapeutic principle is to remove the stimulus, i.e., to treat the associated disease. [285,286,287] The treatment of idiopathic cases, classified as primary urticarial vasculitis syndrome, is difficult and challenging.
Dapsone alone or in combination with other drugs has been one of the various treatment modalities tried in this disease. It has been successful in most [167,288,289,290,291,292,293,294,295], but not all [296,297] of the reported cases.
We think that it is worth a trial in recalcitrant and refractory cases.
Although the usefulness of dapsone has long been recognized in leukocytoclastic vasculitis and is mentioned in this capacity in most of the relevant textbooks and review articles there are very few studies on its effectiveness in this disease and most of them are single case reports. [298,299,300,301,302,303,304,305,306,307] Since the unpredictable waxing and waning course of the disease in its usual form makes the effects of any therapeutic agent difficult to assess, we need more extensive, carefully controlled randomized studies than had been performed until now in order to objectively evaluate the effectiveness of dapsone. On the other hand, even on the basis of our current knowledge, this form of therapy should not be rejected out of hand since it might be of use in a selected group of patients.
|Disease||Drug of choice||Good alternative||Worth a trial||Not recommended|
|Epidermolysis bullosa aquisita||V|
|Erythema elevatum diutinum||V|
|Linear IgA bullous dermatosis||V|
|Linear IgA bullous disease of childhood||V|
|Lupus erythematosus :|
|SLE- vesiculobullous variant||V|
|SLE- urticarial vasculitis||V|
|Panniculitis (alpha-1-antitrypsin deficiency||V|
|Subcorneal pustular dermatosis |
Mechanisms of action of dapsone in dermatological diseases
Dapsone acts against bacteria and protozoa in the same way as sulphonamides,that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. An inflammatory disease which responds to dapsone is almost invariably associated with the infiltration of large numbers of polymorphonuclear leukocytes into the affected tissue. 
Various mechanisms affecting the function of neutrophils have been proposed. Perhaps the best-studied action of dapsone is its interference with the myeloperoxidase-hydrogen peroxide-halide mediated cytotoxic system in neutrophils.
Neutrophils that are recruited at sites of inflammation generate superoxide anion (O2-), which rapidly dismutates to hydrogen peroxide (H2O2). H2O2 is then transformed into hypochlorous acid (HOCl) by neutrophil myeloperoxidase (MPO). As a consequence of its extremely high reactivity, HOCl represents the most toxic and potent oxidant generated by neutrophils, with a potential to cause considerable tissue damage in many inflammatory diseases. This process, the 'respiratory burst', uses large quantities of oxygen, and a single neutrophil may produce enough acid in one second to destroy 150 bacteria.  In the absence of chloride ions or when there is excess hydrogen peroxide, the myeloperoxidase is converted to its inactive form. There are numerous studies which indicate that dapsone reversibly inhibits myeloperoxidase activity by promoting the formation of an inactive intermediate of the enzyme, thus preventing the conversion of hydrogen peroxide to hypochlorous acid, an extremely potent neutrophil oxidant. [309,310,311,312,313,314,315]
Dapsone inhibits neutrophil lysosomal enzymes. In 1974, an experimental model that may allow identification of the effect of sulfones was described.  It is a standard model of hypervitaminosis A causing collapse of the cartilage in rabbit ears. The hypervitaminosis A in rabbits results in the activation of lysosomal enzymes, with the loss of chondroitin sulfate from cartilage. Dapsone prevented this from happening, and this was attributed to inhibition of lysosomal enzyme activity.
Although it has been proven that dapsone interferes with various leukocytes' functions, several authors raised doubts concerning the role of this mechanism in the anti-inflammatory action of the drug.  They argued that the clinical response to dapsone is characterized by the inhibition of accumulation of neutrophils in the skin, rather than the accumulation in the tissue of neutrophils that do not function correctly. Several studies showed that dapsone may impair neutrophil chemotaxis. [321,322,323,324] It was found to inhibit the adherence of neutrophils to the basement membrane zone antibody in a dose-dependent manner. A similar inhibition was also produced when dapsone was added directly to the antibody, which showed that the effect was related directly to the antibody.  Dapsone supressed integrin-mediated neutrophil adherence function.  It also inhibited chemoattractant-induced signal transduction and thus suppressed neutrophil recruitment and local production of toxic products in the affected skin of neutrophilic dermatoses. 
From the above, we can conclude that although the modes of action of dapsone in reducing inflammation are not entirely known, it appears that neutrophils and neutrophil products are the major targets for this drug. While it would be convenient and tidy to ascribe all the effects of dapsone to a single site of action, this does not seem to be the case: the drug might react with neutrophils at more than one location and impair more than one neutrophlic function.
Dapsone therapy may cause a variety of adverse effects, which may be categorized as pharmacologic, dose-dependent, and allergic, or idiosyncratic reactions.
Effective clinical use of dapsone is limited because of dose-dependent adverse hematological reactions, even at the low daily dosages of 100 mg used in the chemotherapy of leprosy and dermatological conditions. Patients with a genetic deficiency of certain enzymes (i.e., glucose-6-phosphate dehydrogenase or glutathione reductase) are more susceptible to the hematological effects.
Long-term administration of dapsone at standard doses (100 mg/d) in normal patients usually results in methemogloginemia of 15%, which is not clinically significant.  The hemotoxicity of dapsone is not caused by the drug itself, but by its hydroxylamine metabolites. The formation of hydroxylamine is catalyzed either by hepatic enzymes such as cytochrome P450, flavin monooxygenase and others, or by myeloperoxidase found in peripheral polymorphonuclear leukocytes.(Figure 1) [332,333,334] Dapsone hydroxylamine reacts with oxyhemoglobin (Fe2+) to form methemoglobin (Fe3+) and nitrosoarene, which, in turn, is reduced to hydroxylamine by either NADPH methemoglobin reductase or glutathione. The hydroxylamine then reacts with another molecule of oxyhemoglobin, thus continuing the redox cycle. Each hydroxylamine molecule is capable of oxidizing up to five oxyhemoglobin molecules, and the cycle only ceases when the erythrocyte is almost totally depleted of glutathione.  Methemoglobinemia occurs to some extent in all patients receiving dapsone and becomes less pronounced as treatment is continued due to an adaptive increase in the activity of NADH-dependent reductase in the erythrocytes. Methemoglobin levels of under 20% are not usually associated with symptoms. Dyspnea, nausea and tachycardia usually occur at levels of 30% or above, while lethargy, stupor and deteriorating consciousness occur as methemoglobin levels approach 55%. Levels of 70% are usually fatal. 
Agranulocytosis is another hematologic adverse effect of dapsone. Unlike methemoglobinemia, this severe adverse effect is due to an unpredictable idiosyncratic reaction. For unknown reasons, the risk of agranulocytosis in patients with dermatitis herpetiformis is more than 25-fold compared with other patients.  Agranulocytosis was estimated to develop in 1 of 240 - 425 patients with dermatitis herpetiformis receiving dapsone therapy, whereas this side effect in patients with leprosy is almost unknown. Factors such as drug dosage, immune status, degree of malnutrition, and ethnic origin are probably important determinants of the risk of developing agranulocytosis.
Another serious idiosyncratic adverse effect is the dapsone hypersensitivity syndrome. Drug hypersensitivity syndrome is a severe idiosyncratic reaction to a drug defined by the clinical triad of fever, rash, and internal organ involvement (most commonly the liver and the hematologic system). It occurs in a relatively small proportion of patients but is associated with considerable morbidity and mortality. The unpredictability and potential severity of this reaction make it a major concern in clinical practice and drug development.
Although this reaction to dapsone is rare considering the widespread use of the drug (particularly in patients receiving multidrug therapy for leprosy), it ranks high among drugs that cause this syndrome. Dapsone-induced hypersensitivity syndrome usually appears four or more weeks after initiation of therapy. Symptoms include a mononucleosis-like rash with fever and lymphadenopathy. Involvement of other organs varies and includes the liver (hepatomegaly, icterus, hepatitis and hepatic encephalopathy), lymphadenopathy, eosinophilia, and others. [46,338,339,340] The course of the disease is also variable, but it may last four weeks or more and fatalities have been reported. [341,342,343,344,345] Exanthematous skin eruptions usually resolve within two weeks of stopping dapsone, although patients in whom Stevens-Johnson syndrome or toxic epidermal necrolysis develops have increased morbidity and mortality.
There is a low and insignificant risk of congenital malformations in patients receiving dapsone during prengnancy. [361,362,363,364,365,366] In lactating mothers, since dapsone diffuses into breast milk  and there are reports of hemolytic anemia induced by this drug transmitted through breast milk , we recommend that if dapsone is required, breast feeding should be discontinued.As for treatment of pregnant patients, it is now generally considered that the benefits of dapsone in the treatment of leprosy and other infectious and non-infectious diseases outweigh any potential risk.
|Methemoglobinemia, hemolysis, anemia|
|Nausea, vomiting, fatigue, anorexia, headache, dizziness|
|Dapsone hypersensitivity syndrome|
|Exanthematous eruption, Stevens-Johnson syndrome, toxic epidermal necrolysis||[346, 347, 348]|
|Peripheral neuropathy||[331, 350, 351, 352, 353, 354]|
|Hepatitis, cholestatic, cytolytic and mixed||[47, 343, 349, 355]|
|Nephritis and renal failure|||
|Psychosis||[357, 358, 359]|
Dapsone is used by millions of patients without serious problems. There are, however, several potentially harmful adverse effects that necessitate careful monitoring of patients under this treatment.
Dapsone is considered unsafe and should not be used in the following conditions: severe anemia, porphyria, deficiency of glucose-6-phosphate dehydrogenase, glutathione reductase or methemoglobin reductase, allergy to sulfonamides, or significant liver disease. It should not be paired with other hemolytics or dideoxyinosine. Before starting therapy, a complete blood count, reticulocyte count, glucose-6-phosphate dehydrogenase level, liver function studies, urinanalysis and renal function tests should be performed. During therapy, complete blood count, reticulocyte count, platelet count and leukocyte count with differential should be obtained weekly for the first month, then twice per month during the next two months and every three months thereafter. Liver and renal function should be tested every three months. Methemoglobin levels should be obtained in patients who become symptomatic for methemoglobinemia.
References1. Doull J. Sulfone therapy of leprosy. Background, early history and present status. Int J Lepr Other Mycobact Dis 1963; 31:143-160.
2. Wozel G. The story of sulfones in tropical medicine and dermatology. Int J Dermatol 1989; 28:17-21.
3. Shepard C. Leprosy today. N Engl J Med 1982; 307:1640-1641.
4. Waters M. New approaches to chemotherapy for leprosy. Drugs 1983; 26:465-467.
5. Chiodini P. The chemoprophylaxis of malaria. J Antimicrob Chemother 1987; 20:297-302.
6. Powell R, DeGowin R, Eppes R, McNamara J, Carson P. The antimalarial and hemolytic properties of 4,4'-diaminodiphenylsulfone (DDS). Int J Lepr Other mycobact Dis 1967; 35:590-604.
7. Lee B, Medina I, Benowitz N, et al. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of Pneumocystic carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med 1989; 110:606-611.
8. Hughes W, Smith B. Efficacy of diaminodiphenylsulfone and other drugs in murine penumocystis carinii pneumonitis. Antimicrob Agents Chemother 1984; 26:436-440.
9. Leoung G, Milles J, Hopewell P, et al. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:45-48.
10. Bernstein J, Lorincz A. Sulfonamides and sulfones in dermatologic therapy. Int J Dermatol 1981; 20:81-88.
11. Lang P. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979; 1:479-492.
12. Lorincz A, Pearson R. Sulfapyridine and sulphone drugs in dermatology. Arch Dermatol 1962; 85:42-56.
13. Wozel G, Hackert I. Sulfone - dermatologische Indikationen und Nebenwirkungen in einer Uebersicht. Dermatol Monatsschr 1986; 172:513-522.
14. Smith E, Zone J. Dermatitis herpetiformis and linear IgA bullous dermatosis. Dermatol Clin 1993; 11:511-526.
15. Leonard J, Fry L. Treatment and management of dermatitis herpetiformis. Clin Dermatol 1991; 9:403-408.
16. Fry L. The treatment of dermatitis herpetiformis. Clin Exp Dermatol 1982; 7:633-642.
17. Fromm E, Wittmann J. Derivate des p-nitrophenols. Berichte Deutsch Chem Ges 1908; 41:2264-2273.
18. Dogmagk G. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Deutsch Med Wschr 1935; 61:250-253.
19. Dogmagk G. Eine neue Klasse von Desinfectionsmitteln. Deutsch Med Wschr 1935; 61:829-832.
20. Buttle G, Stephenson D, Smith S, et al. The treatment of streptococcal infections in mice with 4:4'diaminodiphenylsulfone. Lancet 1937; 1:1331-1334.
21. Fourneau E, Trefouel J, Nitti F, et al. Action anti-streptococcique des derives sulfures organiques. Compt Rend Acad Sci 1937; 204:1763-1766.
22. Pohls P. Die chemotherapeutische Wirksamkeit des 4,4'-diaminodiphenylsulfones und seiner Derivate. Angew Chem 1949; 61:188-190.
23. Heitz B, Nitti F, Trefouel J. Note preliminaire sur l'action de la para-diacetyl-aminodiphenyl sulfone (1399F) dans la blennorrhagic. Bull Soc Franc Dermatol Syphilol 1937; 44:1889.
24. Feinstone W, Bliss E, Ott E, et al. Observations concerning the toxicity, absorption and therapeutic effect of sulphoanilamide and certain related organic sulphur-containing compounds in experimental infections in mice. Bull Johns Hopkins Hosp 1938; 62:565-592.
25. Cowdry E, Ruangsiri C. Influence of promin, starch and hepataldehyde on experimental leprosy in rats. Arch Pathol 1941; 32:632-640.
26. Feldman W, Hinshaw H, Moses H. Effect of promin (sodium salt of p,p'diaminodiphenyl-sulfone-N-'didextrose sulfate) on experimental tuberculosis: preliminary report. Proc Staff Meet Mayo Clinic 1940; 15:695-699.
27. Faget G, Pogge R, Johansen F, Dinan J. The promin treatment of leprosy. Pub Health Rep 1943; 58:1729-1741.
28. Cochrane R, Ramanujam H, Paul H, et al. Two-and-a-half years' experimental work on the sulphone group of drugs. Lepr Rev 1949; 20:4-64.
29. Esteves J, Brandao F. Acerca da accao das sulfamideas e das sulfoneas na doenca de Duhring. Trab Soc Pertuguesa Dermatol Venereol 1950; 8:209-217.
30. Cornbleet T. Sulfoxone (Diasone) sodium for dermatitis herpetiformis. AMA Arch Dermatol Syphilol 1951; 64:684-687.
31. Zuidema J, Hilbers-Modderman E, Merkus F. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11:299-315.
32. Ellard G. Absorption, metabolism and excretion of di (rho-aminophenyl) sulphone (dapsone) and di (rho-amonophenyl) sulphoxide in man. Br J Pharmacol 1966; 26:212-217.
33. Ellard G, Gammon P, Rees R. Dapsone acetylation and the treatment of leprosy. Nature 1972; 239:159-160.
34. Mitra A, Thummel K, Kalhorn T, Kharasch E, Unadkat J, Slattery J. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58:556-566.
35. Fliming C, Branch R, Wilkinson G, Guengerich F. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41:975-980.
36. Vague C, Svensson C. Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P450 2C6/2C11 and 3A1. Drug Metab Dispos 1994; 22:572-577.
37. Guengerich F, Humphreys W, Yun C, Hammons G, Kadlubar F, Seto Y, et al. Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues. Princess Takamatsu Symp 1995; 23:78-84.
38. Coleman M, Jacobus D. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. Biochem Pharmacol 1993; 45:1027-1033.
39. Ross C. Treatment of acne vulgaris with dapsone. Br J Dermatol 1961; 73:367-370.
40. Kaminsky C, Kaminsky A, Schicci C, Velazco de Morini M. Acne: Treatment with diaminodiphenylsulfone. Cutis 1974; 13:869-871.
41. Geniaux M, Meraud J, Texier L. Experience de la disulfone dans le treaitement de l'acne nodulaire grave. Larc Medical (Lille) 1981; 1:67.
42. Prendiville J, Logan R, Russel-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Br J Dermatol 1988; 13:67-71.
43. Corp C, Ghishan F. The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris. J Pediatr Gastroenerol Nutr 1998; 26:103-105.
44. Ismail R. Acne fulminans with dapsone induced haemolysis: a case report. Med J Malaysia 1987; 42:124-126.
45. Endre Z, Charlesworth J, Macdonald G, Woodbridge L. Successful treatment of acute dapsone intoxication using charcoal hemoperfusion. Aust N Z J Med 1983; 13:509-512.
46. Tomecki K, Catalano C. Dapsone hypersensitivity. The sulfone syndrome revisited. Arch Dermatol 1981; 117:38-39.
47. Stone S, Goodwin R. Dapsone-induced jaundice. Arch Dermatol 1978; 114:947.
48. Koller W, Gehlmann L, Malkinson F, Davis F. Dapsone-induced peripheral neuropathy. Arch Neurol 1977; 34:644-646.
49. Stern RS. Acne therapy. Medication use and sources of care in office-based practice. Arch Dermatol 1996; 132:776-780.
50. Kellett J, Beck M, Chalmers R. Erythema nodosum and circulating immune complexes in acne fulminans after treatment with isotretinoin. Br Med J 1985; 290:820.
51. Blanc D, Zultak M, Wendling D, Lonchampt F. Eruptive pyogenic granulomas and acne fulminans in two siblings treated with isotretinoin: a possible common pathogenesis. Dermatologica 1988; 177:16-18.
52. Cavicchini S, Ranza R, Brezzi A, et al. Acne fulminans with sacroiliitis during isotretinoin therapy. Eur J Dermatol 1992; 2:327-328.
53. Coi E, Bang D. Acne fulminans and 13-cis-retinoic acid. J Dermatol 1992; 19:378-383.
54. Joly P, Prost C, Gaudemar M, Revuz J. Acne fulminans declenchee par la prise d'isotretinoine. Ann Dermatol Venereol 1991; 118:369-372.
55. Tan B, Lear J, Smith A. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26-27.
56. Traupe H, von Muhlendahl K, Bramswig J, Happle R. Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol 1988; 124:414-417.
57. Von den Driesch P, Schell H, Haneke E. Acne fulminans: Therapie mit 13-cis-Retinsaure un Indomatazin. Z Hautkr 1986; 61:1145-1151.
58. Hatmann R, Plewig G. Acne fulminans: tratamento de 11 pacientes com o acido 13-cis-retinoico. Ann Bras Dermatol 1983; 58:3-10.
59. Jansen T, Plewig G. Acne fulminans. Int J Dermatol 1998; 37:254-257.
60. Wolf R, David M, Feuerman E. Acne with acute systemic reaction (acne fulminans?). Report of a case. Cutis 1981; 28:210-211.
61. Siegel D, Stronsberg J, Wiese F, Chen J. Acne fulminans with a lytic bone lesion responsive to dapsone [Letter]. J Rheumatol 1982; 9:344-346.
62. Ghate J, Jorizzo J. Behcet's disease and complex aphthosis. J Am Acad Dermatol 1999; 40:1-18.
63. Sharquie K. Suppression of Behcet disease with dapsone. Br J Dermatol 1984; 110:493-494.
64. Convit J, Goihman-Yahr M, Tondon-Lugo A. Timoma, hipogammaglobulinemia y sindrome de Behcet (informe de un caso). Medicina Cutanea (Spain) 1972; 6:209-216.
65. Jacyk W. Behcet's disease in South African blacks: report of five cases. J Am Acad Dermatol 1994; 30:869-873.
66. Mangelsdorf H, White W, Jorizzo J. Behcet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol 1996; 34:745-750.
67. Lever W. Pemphigus. Medicine (Baltimore) 1953; 32:1-123.
68. Lever W. Pemphigus and pemphigoid. Springfield: Charles C Thomas Publisher, 1965.
69. Costello M. Sulfapyridine in the treatment of dermatitis herpetiformis. Arch Dermatol Syphilol 1947; 56:614-624.
70. Tolman M, Moschella S, Schneiderman R. Dermatitis herpetiformis --specific entity or clinical complex? J Invest Dermatol 1959; 32:557-560.
71. Spier H, Thies W. Zur Sulfonbehandlung der dermatitis herpetiformis Duhring. Hautarzt 1955; 6:415-418.
72. Rook A, Waddington E. Pemphigus and pemphigoid. Br J Dermatol 1953; 65:425-431.
73. Honeyman J, Honeyman A, Lobitz W Jr, Storrs F. The enigma of bullous pemphigoid and dermatitis herpetiformis. Arch Dermatol 1972; 106:22-25.
74. Piamphongsant T, Ausawamongkonpan S. Bullous pemphigoid controlled by dapsone. Dermatologica 1976; 152:352-357.
75. Piamphongsant T, Chaikittisilpa S, Kullavanijaya P. Bullous pemphigoid in childhood: report of three cases and a review of literature. Int J Dermatol 1977; 16:126-133.
76. Van der Meer J. Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. Br J Dermatol 1969; 81:493-503.
77. Chorzelski T, Jablonska S. Diagnostic significance of immunofluorescent pattern in dermatitis herpetiformis. Int J Dermatol 1975; 14:429-436.
78. Stone S. Bullous pemphigoid. Arch Dermatol 1974; 110:812.
79. Person J, Rogers R III. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc 1977; 52:54-66.
80. Person J, Rogers R III. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113:610-615.
81. Venning V, Millard P, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989; 120:83-92.
82. Jeffes E, Ahmed A. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989; 14:132-136.
83. Piamphongsant T. Dapsone for the treatment of bullous pemphigoid. Asian Pac J Allergy Immunol 1983; 1:19-21.
84. Piamphongsant T, Sirimachan S, Himmunknan P. Juvenile blistering diseases: the problems of diagnosis and treatment. Asian Pac J Allergy Immunol 1986; 4:133-137.
85. Venning V, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26:585-589.
86. Bouscarat F, Chosidow O, Picard-Dahan C, Sakiz V, Crickx B, Prost C, et al. Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34:683-684.
87. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989; 20:458-461.
88. Rogers R III, Seehafer J, Perry H. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215-223.
89. Tauber J, Sainz-de-la-Maza M, Foster C. Systemic chemotherapy for ocular pemphigoid. Cornea 1991; 10:185-195.
90. Fern A, Jay J, Young H, MacKie R. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992; 76:332-335.
91. Foster C, Neumann R, Tauber J. Long term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol 1992; 82:223-229.
92. Elder M, Leonard J, Dart J. Sulphapyridine -- a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80:549-552.
93. Mobini N, Nagarwalla N, Ahmed R. Oral pemphigoid. Subset of cicatricial pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:37-43.
94. Nguyen Q, Foster C. Cicatricial pemphigoid: diagnosis and treatment. Int Ophthalmol Clin 1996; 36:41-60.
95. Mutasim D, Pelc N, Anhalt G. Cicatricial pemphigoid. Dermatol Clin 1993; 11:499-510.
96. Anhalt G. Pemphigoid bullous and cicatricial. Dermatol Clin 1990; 8:701-716.
97. Ahmed A, Kurgis B, Rogers R III. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24:987-1001.
98. Rogers R III, Mehregan D. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7:201-205.
99. Rogers R III. Dapsone and sulfapyridine therapy of pemphigoid diseases. Australas J Dermatol 1986; 27:58-63.
100. Foster C. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527-663.
101. Gammon W, Briggaman R. Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus: diseases of autoimmunity to type VII collagen. Dermatol Clin 1993; 11:535-547.
102. Arpey C, Elewski B, Moritz D, Gammon R. Childhood epidermolysis bullosa acquisita: report of three cases and review of literature. J Am Acad Dermatol 1991; 24:706-714.
103. McCuaig C, Chan L, Woodley D, Rasmussen J, Cooper K. Eidermolysis bullosa acquisita in childhood: differentiation from hereditary epidermolysis bullosa. Arch Dermatol 1989; 125:944-949.
104. Rubenstein R, Esterly N, Fine J. Childhood epidermolysis bullosa acquisita: detection in a 5-year-old girl. Arch Dermatol 1987; 123:772-776.
105. Roger H, Machado P, Nicolas J, et al. Epidermolysis bullosa acquisita in a 3 1/2-year-old girl. J Am Acad Dermatol 1992; 27:858-862.
106. Espagne E, Prost C, Janssen F, et al. Epidermolyse bulleuse acquise de l'enfant. Ann Dermatol Venereol 1990; 117:814-816.
107. Inauen P, Hunziker T, Gerber H, Bruckner-Tuderman L, Braathen L. Childhood epidermolysis bullosa acquisita. Br J Dermatol 1994; 131:898-900.
108. Callot-Mellot C, Bodemer C, Caux F, Bourgault-Villada I, Fraitag S, Goudie G, et al. Epidermolysis bullosa acquisita in childhood. Arch Dermatol 1997; 133:1122-1126.
109. Krahe J, Galal O, Kordass U, Bornemann P. Epidermolysis bullosa atrophicans gravis. Report of a therapeutic trial with dapsone. Monatsschr Kinderheilkd 1988; 36:140-142.
110. Lacour J, Bernard P, Rostain G, Baechler-Sadoul E, Pisani A, Ortonne J. Childhood acquired epidermolysis bullosa. Pediatr Dermatol 1995; 12:16-20.
111. Su J, Varigos G, Dowling J. Epidermolysis bullosa acquisita in childhood. Australas J Dermatol 1998; 39:38-41.
112. Hayashi K, Ueda M, Sakai M, Fujikawa Y, Tsuru K, Amagai M, et al. Epidermolysis bullosa acquisita in a 6-year-old Japanese boy. Int J Dermatol 1998; 37:612-614.
113. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hinter H, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34:331-335.
114. Mohr C, Sunderkotter C, Hildebrand A, Biel K, Rutter A, Rutter G, et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995; 132:824-826.
115. Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita--successful treatment with colchicine. Arch Dermatol Res 1994; 286:35-46.
116. Furue M, Iwata M, Yoon H, Kubota Y, Ohto H, Kawashima M, et al. Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer. J Am Acad Dermatol 1986; 14:873-878.
117. Yiannias J, El-Azhary R, Gobson L. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dermatol 1992; 26:38-44.
118. Requena L, Sanchez-Yus E, Martin L, Barat A, Arias D. Erythema elevatum diutinum in a patient with acquired immunodeficiency syndrome. Another clinical simulator of Kaposi's sarcoma. Arch Dermatol 1991; 127:1819-1822.
119. Farella V, Lotti T, Difonzo E, Panconesi E. Erythema elevatum diutinum. Int J Dermatol 1994; 33:638-640.
120. Hansen U, Haerslev T, Knudsen B, Jacobsen G. Erythema elevatum diutinum: case report showing an unusual distribution. Cutis 1994; 53:124-126.
121. Miyagawa S, Kitamura W, Morita K, Saishin M, Shirai T. Association of hyperimmunoglobulinaemia D syndrome with erythema elevatum diutinum. Br J Dermatol 1993; 128:572-574.
122. Gerbig A, Zala L, Hunziker T. Erythema elevatum diutinum. Eine seltene Dermatose mit einem breiten Spektrum assoziierter Erkrankungen. Hautarzt 1997; 48:113-117.
123. Dronda F, Gonzalez-Lopez A, Lecona M, Barros C. Erythema elevatum diutinum in human immunodeficiency virus-related patients -- report of a case and review of the literature. Clin Exp Dermatol 1996; 21:222-225.
124. Ramsey M, Gibson B, Tschen J, Wolf JJ. Erythema elevatum diutinum. Cutis 1984; 34:41-43.
125. Fort S, Rodman O. Erythema elevatum diutinum. Response to dapsone. Arch Dermatol 1977; 113:819-822.
126. Cream J, Levene G, Calnan C. Erythema elevatum diutinum: an unusual reaction to streptococcal antigen and response to dapsone. Br J Dermatol 1971; 84:393-399.
127. Vollum D. Erythema elevatum diutinum -- vesicular lesions and sulphone response. Br J Dermatol 1968; 80:178-183.
128. Katz S, Gallin J, Hertz K, Fauci A, Lawley T. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore) 1977; 56:443-455.
129. Takiwaki H, Kubo Y, Tsuda H, Arase S, Shioto H. Peripheral ulcerative keratitis associated with erythema elevatum diutinum and a positive rheumatoid factor: a report of three cases. Br J Dermatol 1998; 138:893-897.
130. Wilkinson S, English J, Smith N, Wilson-Jones E, Winkelmann R. Erythema elevatum diutinum: a clinicopathological study. Clin Exp Dermatol 1992; 17:87-93.
131. Fredenberg J, Malkinson F. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987; 16:772-778.
132. Proneuf M, Duterque M, Sotto A, Jourdan J. Unusual erythema elevatum diutinum with fibrohistiocytic proliferation. Br J Dermatol 1996; 134:1131-1134.
133. Poulsen A, Hultberg B, Thomsen K, Wantzin G. Regression of Kaposi's sarcoma in AIDS after treatment with dapsone [letter]. Lancet 1984; 1:560.
134. Poulsen A, Hultberg B, Thomsen K, Lange-Wantzin G. Dapsone in the treatment of Kaposi's sarcoma. Acta Derm Venereol (Stockh) 1984; 64:561-563.
135. Hruza G, Friedman-Kien A, Laubenstein L, Wernz J, Lifshitz M, Rubinstein P. Dapsone for AIDS-associated Kaposi's sarcoma [letter]. Lancet 1985; 1:642.
136. De Haas E, de Wit R, van Volten W. Non-HIV-related Kaposi's sarcoma suppressed by dapsone. Br J Dermatol 1996; 135:813-814.
137. Chorzelski T, Jablonska S, Beutner E. Adult form of linear IgA bullous dermatosis. In: Beutner E, Chorzelski T, Bean S, editors. Immunopathology of the Skin. New York: Wiley, 1979:316-319.
138. Fry L, Seah P. Dermatitis herpetiformis: an evaluation of diagnostic criteria. Br J Dermatol 1974; 90:137-146.
139. Yoita H, Katz S. Immunoelectronmicroscopic localization of IgA in skin of patients with dermatitis herpetiformis. J Invest Dermatol 1976; 67:502-506.
140. Pehamberger H, Bschnait F, Konrad K, Holubar K. Bullous pemphigoid, herpes gestationis and linear dermatitis herpetiformis: circulating anti-basement membrane zone antibodies; in vitro studies. J Invest Dermatol 1980; 74:105-108.
141. Provost T, Maize J, Ahmed R, Strauss J, Dobson R. Unusual subepidermal bullous disease with immunologic features of bullous pemphigoid. Arch Dermatol 1979; 115:156-160.
142. Honeyman J, Honeyman A, De la Parra M, Pinto A, Eguiguren G. Polymorphous pemphigoid. Arch Dermatol 1979; 115:423-427.
143. Jablonska S, Chorzelski T, Beutner E, Maciejowska E, Rzesa G. Dermatitis herpetiformis and bullous pemphigoid. Intermediate and mixed forms. Arch Dermatol 1976; 112:45-48.
144. Chorzelski T, Jablonska S. IgA linea dermatosis of childhood (chronic bullous disease of childhood). Br J Dermatol 1979; 101:535-542.
145. Lawley T, Strober W, Yoita H, Katz S. Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits. J Invest Dermatol 1980; 74:9-12.
146. Fry L, Seah P, Riches D, Hoffbrand A. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet 1973; 1:288-291.
147. Fry L, Leonard J, Swain W, Haffenden G, Ring N, McMinn R. Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107:631-640.
148. Wojnarowska F, Marsden R, Bhogal B, Black M. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988; 19:792-805.
149. Chorzelski T, Jablonska S, Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol 1991; 9:383-392.
150. Jablonska S, Chorzelski T. When and how to use sulfones in bullous diseases. Int J Dermatol 1981; 20:103-105.
151. Wilson B, Beutner E, Kumar V, Chorzelski T, Jablonska S. Linear IgA bullous dermatosis. An immunologically defined disease. Int J Dermatol 1985; 24:569-574.
152. Kuechle M, Stegemeir E, Maynard B, Gibson L, Leiferman K, Peters M. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30:187-192.
153. Tonev S, Vasileva S, Kadurina M. Depot sulfonamid associated linear IgA bullous dermatosis with erythema multiforme-like clinical features. J Eur Acad Dermatol Venereol 1998; 11:165-168.
154. Wojnarowska F, Bhogal B, Black M. Chronic bullous disease of childhood and linear IgA disease of adults are IgA1-mediated diseases. Br J Dermatol 1994; 131:201-204.
155. Bhogal B, Wojnarowska F, Marsden R, Das A, Black M, McKee P. Linear IgA bullous dermatosis of adults and children: an immunoelectron microscopic study. Br J Dermatol 1987; 117:289-296.
156. Chorzelski T, Jablonska S. Evolving concept of IgA linear dermatosis. Semin Dermatol 1988; 7:225-232.
157. Jablonska S, Chorzelski T, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol 1991; 9:393-401.
158. Surbrugg S, Weston W. The course of chronic bullous disease of childhood. Pediatr Dermatol 1985; 2:213-215.
159. Marsden R. The treatment of benign chronic bullous dermatosis of childhood, and dermatitis herpetiformis and bullous pemphigoid beginning in childhood. Clin Exp Dermatol 1982; 7:653-663.
160. Rogers M, Bartlett B, Walder B, Cains G. Chronic bullous disease of childhood: aspects of management. Austral J Dermatol 1982; 23:62-69.
161. Easterly N, Furey N. Chronic bullous dermatosis of childhood. Arch Dermatol 1997; 113:42-46.
162. Witkamp L, Sillevis Smitt J. Linear IgA dermatosis of childhood. Br J Dermatol 1991; 125:395-396.
163. Edwards S, Wojnarowska F. Chronic bullous disease of childhood in three patients of Polynesian extraction. Clin Exp Dermatol 1990; 15:367-369.
164. O'Loughlin S, Schreter A, Jordon R. Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases. Arch Dermatol 1978; 114:879-883.
165. Matthews C, Saihan E, Warin R. Urticaria-like lesions associated with systemic lupus erythematosus: Response to dapsone. Br J Dermatol 1978; 99:555
166. Ruzicka T, Goerz G. Systemic lupus erythematosus and vasculitis urticaria. Effect of dapsone and complement levels. Dermatologica 1981; 162:203-205.
167. Holtman J, Neustadt D, Klein J, Callen J. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990; 17:1222-1225.
168. Hall R, Lawley T, Smith H, Katz S. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 97:165-170.
169. Burrows M, Bhogal B, Black M, Rustin M, Ishida-Yamamoto A, Kirtsching G, et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol 1993; 128:332-338.
170. Camisa C. Vesiculobullous systemic lupus erythematosus. A report of four cases. J Am Acad Dermatol 1988; 18:93-100.
171. Singh Y, Adya C, Verma K, Kumar A, Malaviya A. Dapsone in cutaneouis lesions of SLE: an open study. J Assoc Physicians India 1992; 40:735-736.
172. Tsufsui K, Imai T, Hatta N, Takata M, Takehara K. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone. J Am Acad Dermatol 1996; 35:313-315.
173. McCormack L, Elgart M, Turner M. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984; 11:397-401.
174. Moss C, Hamilton P. Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. Br Med J 1988; 297:266.
175. Nishina M, Saito E, Kinoshita M. Correction of severe leukopenia and thrombocytopenia in systemic lupus erythematosus by treatment with dapsone. J Rheumatol 1997; 24:811-812.
176. Lindkov R, Reymann F. Dapsone in the treatment of cutanous lupus erythematosus. Dermatologica 1986; 172:214-217.
177. Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981; 104:53-56.
178. Coburn L, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982; 106:105-106.
179. Shimizu A, Ishikawa O, Nagai Y, Mikami Y, Nishimura K. Primary cutaneous nocardiosis due to Nocardia nova in a healthy woman. Br J Dermatol 2001; 145:154-156.
180. Welsh O. Mycetoma. Semin Dermatol 1993; 12:290-295.
181. Venugopal P, Venugopal T. Actinomadura madurae causing mycetomas in Madras. Indian J Pathol Microbiol 1991; 34:119-125.
182. Ponico Mendes R, Negroni R, Bonifaz A, Pappagianis D. New aspects of some endemic mycoses. Med Mycol 2000; 38:237-241.
183. Izarn R, Reguer M. A case of actinomycetes mycetoma in Burundi. Bull Soc Pathol Exot Filiales 1984; 77:649-652.
184. Biagini R, Martinez T, Museli A, Sarmiento Villa H. Mycetoma in northern Argentina. Med Cutan Ibero Lat Am 1983; 11:431-436.
185. Kakande I. Treatment of mycetoma with a combination of dapsone and sulfa-trimoxazole. East Afr Med J 1979; 56:49-53.
186. Bezes H, Courbil L, Morin P, Beaumont R. Tactic for treatment of African mycetomas. Med Trop (Mars) 1979; 39:41-51.
187. Rogers RIII, Muller S. Treatment of actinomycetoma with dapsone. A report of infection with Nocardia asteroides. Arch Dermatol 1974; 109:529-534.
188. Warter J, Storck D, Grosshans E, Metais P, Kuntz J, Klumpp T. Syndrome de Weber-Christian associe a un deficit en alpha-1-antitrypsine; enquete familiale. Ann Med Interne (Paris) 1972; 123:877-882.
189. Smith K, Su D. Clinical and pathologic correlation in 96 patients with panniculitis, including 15 patients with deficient levels of a1-antitrypsin. J Am Acad Dermatol 1989; 21:1192-1196.
190. Smith K, Pittelkow M, Su W. Panniculitis associated with severe alpha 1-antitrypsin deficiency. Treatment and review of the literature. Arch Dermatol 1987; 123:1655-1661.
191. Irvine C, Neild V, Stephens C, Black M. Alpha-1-antitrypsin deficiency panniculitis. J R Soc Med 1990; 83:743-744.
192. Edmonds B, Hodge J, Rietschel R. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol 1991; 8:296-299.
193. Martinon-Sanchez F, Fernandez-Villar M, Otero-Esteban J, Garcia-Rodriguez J. Panniculitis associated with alpha 1-antitryptin deficiency. An Esp Pediatr 1993; 38:269-270.
194. Schadendorf D, Haas N, Nurnberger F, Czarnetzki B. Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy [letter]. Hautarzt 1993; 44:653-657.
195. Wozel G. Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy [letter]. Hautarzt 1994; 45:580-581.
196. Shields R, Su W. 35-year-old woman with ulcerating skin lesions. Mayo Clin Proc 1996; 71:59-62.
197. Wolf R, Landau M, Tur E, Brenner S. Early treatment of pemphigus does not improve the prognosis. A review of 53 patients. J Eur Acad Dermatol Venereol 1995; 4:131-136.
198. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol 1976; 94:681-686.
199. Basset N, Guillot B, Michel B, Meynadier J, Guilhou J. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987; 123:783-785.
200. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978; 156:120-123.
201. Rosenberg F, Sanders S, Nelson C. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112:962-970.
202. Bjarnason B, Skoglund C, Flosadottir E. Childhood pemphigus vulgaris treated with dapsone: a case report. Pediatr Dermatol 1998; 15:381-383.
203. Ahmed A, Salm M. Juvenile pemphigus. J Am Acad Dermatol 1983; 8:799-807.
204. Amerian M, Ahmed A. Pemphigus erythematosus. Presentation of four cases and review of literature. J Am Acad Dermatol 1984; 10:215-222.
205. Leibowitz M, Voss S. Juvenile pemphigus foliaceous: response to dapsone. Arch Dermatol 1993; 129:910
206. Galambrun C, Cambazard F, Clavel C, Versini P, Stephan J. Pamphigus foliaceus. Arch Dis Child 1997; 77:255-257.
207. Mehravaran M, Morvay M, Molnar K, Olah J, Korom I, Husz S, et al. Juvenile pemphigus foliaceus. Br J Dermatol 1998; 139:496-499.
208. Jeffes E3, Kaplan R, Ahmed A. Acantholysis produced in vitro with phmphigus serum: hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis. J Clin Immunol 1984; 4:359-363.
209. Hashimoto K, Singer K, Lazarus G. The effect of corticosteroids, dapsone and gold uon plasminogen activator eynthesis and secretion by human epidermal cells cultured with pemphigus antibody. Br J Dermatol 1984; 110:297
210. Jablonska S, Chorzelski T, Beutner E, Chorzelska J. Herpetiform pemphigus, a variable pattern of phemphgus. Int J Dermatol 1975; 14:353-359.
211. Floden C, Gentale H. A case of clinically typical dermatitis herpetiformis (M. Duhring) presenting acantholylysis. Acta Derm Venereol (Stockh) 1955; 35:128
212. Ingber A, Feuerman E. Pemphigus with characteristics of dermatitis herpetiformis. A long-term follow-up of five patients. Int J Dermatol 1986; 25:575-579.
213. Mciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity? Int J Dermatol 1987; 26:571-577.
214. Kubo A, Amagai M, Hashimoto T, et al. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (dermoglein 3). Br J Dermatol 1997; 137:109-113.
215. Micali G, Musumeci M, Nasca M. Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int J Dermatol 1998; 37:197-200.
216. Seah P, Fry L, Cairns R, Feiwel M. Pemphigus controlled by sulphapyridine. Br J Dermatol 1973; 89:77-81.
217. Haensch R. Pemphigus herpetiformis. Hautarzt 1979; 30:418-422.
218. Huilgol S, Black M. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995; 20:283-293.
219. Huff J, Golitz L, Kunke K. Intraepidermal neutrophilic IgA dermatosis. N Engl J Med 1985; 313:1643-1645.
220. Beutner E, Chorzelski T, Wilson R, et al. IgA pemphigus foliaceus. J Am Acad Dermatol 1989; 20:89-97.
221. Wallach D. Intraepidermal IgA pustulosis. J Am Acad Dermatol 1992; 27:993-1000.
222. Niimi Y, Kawana S, Kusunoki T. IgA pemphigus: A case report and its characteristic clinical features compared with subcorneal pustular dermatosis. J Am Acad Dermatol 2000; 43:546-549.
223. Hodak E, David M, Ingber A, et al. The clinical and histopathological spectrum of IgA-pemphigus: report of two cases. Clin Exp Dermatol 1990; 15:433-437.
224. Ongenae K, Temmerman L, Vermander F, Naeyaert J. Intercellular IgA dermatosis. Eur J Dermatol 1999; 9:85-94.
225. Yasuda H, kobayashi H, Hashimoto T, Itoh K, Yamane M, Nakamura J. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol 2000; 143:144-148.
226. Brunsting L, Goeckerman W, O'Leary P. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol 1930; 22:655-680.
227. Perry H, Brunsting L. Pyoderma gangrenosum: a clinical study of 19 cases. Arch Dermatol 1957; 75:380-386.
228. Ayres S, Ayres SI. Pyoderma gangrenosum with an unusual syndrome of ulcers, vesicles, and arthritis. Arch Dermatol 1958; 77:269-280.
229. Lorincz A, Pearson R. Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 1962; 85:42-54.
230. Powell F, Perry H. Pyoderma gangrenosum in childhood. Arch Dermatol 1984; 120:757-761.
231. Altman J, Mopper C. Pyoderma gangrenosum treated with sulfone drugs. Minn Med 1966; 49:22-26.
232. Brown R, Lay L, Graham D. Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg (Br) 1993; 18:119-121.
233. Soto L. Diaminodiphenylsulfone and steroids in the treatment of pyoderma gangrenosum. Int J Dermatol 1970; 9:293-300.
234. Fardal R. Pyoderma gangrenosum. Cutis 1968; 4:979-980.
235. Galun E, Flugelman M, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81:988-989.
236. Anderson J. Malignant pyoderma. Br J Dermatol 1978; 99:211-214.
237. Perry H, Winkelmann R, Muller S, Kierland R. Malignant pyodermas. Arch Dermatol 1968; 98:561-574.
238. Wenikoff S, Merritt C, Briggaman R, Woodley D. Malignant pyoderma or pyoderma gangrenosum of the head and neck? Arch Dermatol 1987; 123:371-375.
239. Erdi H, Anadolu R, Piskin G, Gurgey E. Malignant pyoderma: a clinical variant of pyoderma gangrenosum. Int J Dermatol 1996; 35:811-813.
240. Jaksch-Wartenhorst R. Polychondropathia. Wien Arch Inn Med 1923; 6:93-100.
241. McAdam L, O'Hanlan M, Bluestone R, Pearson C. Relaptins polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Bartimore) 1976; 55:193-215.
242. Martin J, Roenigk HJ, Lynch W, Tingwald F. Relapsing polychondritis treated with dapsone. Arch Dermatol 1976; 112:1272-1274.
243. Barranco V, Minor D, Solomon H. Treatment of relapsing polychondritis with dapsone. Arch Dermatol 1976; 112:1286-1288.
244. Damiani J, Levine H. Relapsing polychondritis -- report of ten cases. Laryngoscope 1979; 89:929-946.
245. Carpenter J, Macaulay W. Relapsing polychondritis [letter]. Arthritis Rheum 1979; 22:204-205.
246. Hanslik T, Wechsler B, Piette J, Vidailhet M, Robin P, Godeau P. Central nervous system involvement in relapsing polychondritis. Clin Exp Dermatol 1994; 12:539-541.
247. White JJ. Relapsing polychondritis. South Med J 1985; 78:448-451.
248. Estes S. Relapsing polychondritis. A case report and literature review. Cutis 1983; 32:471-476.
249. Espinoza L, Richman A, Bocanegra T, Pina I, Vasey F, Rifkin S, et al. Immune complex-mediated renal involvement in relapsing polychondritis. Am J Med 1981; 71:181-183.
250. Liot F, Lemaigre D, Dessanges J, Leroy M. Polychondrite chronique atrophiante avec atteinte respiratoire predominante. Traitment par les sulfones. Interet de l'exploration functionnelle. Ann Med Interne Paris 1980; 131:519-524.
251. Waller E, Raebel M. Relapsing polychondritis in a Latin American man. Am J Hosp Pharm 1979; 36:806-810.
252. Deschapmos P, Leroy D, Mandard J, Benard Y. Traitement de la polychondrite chronique atrophiante par les sulfones. Une observation. Nouv Presse Med 1978; 7:2549-2552.
253. Gouet D, Marechaud R, neau J, Abadie J, Rossi F, Sudre Y. Polychondrite chronique atrophiante. Analyse critique de l'efficacite therapeutique de la dapsone. Deux observations. Presse Med 1984; 13:723-726.
254. Svenson K, Holmdahl R, Klareskog L, Wibell L, Sjoberg O, Klintmalm G, et al. Cyclosporine A treatment in a case of relapsing polychondritis. Scand J Rheumatol 1984; 13:329-333.
255. Jourdain O, Valdazo A, Papillard T, Raynal F. La polychondrite chronique atrophiante. A propos de 4 observations. Rev Laryngol Otol Rhinol Bord 1989; 110:161-164.
256. Trepel R, Lipnick R, D'Angelo L. Relapsing polychondritis in an adolescent. J Adolesc Health Care 1989; 10:557-560.
257. Lim M, Chan H. Relapsing polychondritis -- a report on two Chinese patients with severe costal chondritis. Ann Acad Med Singapore 1990; 19:396-403.
258. Smith C, Micks D. The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, Loxoceles recluse. Lab Invest 1976; 22:90-93.
259. King LJ, Rees R. Dapsone treatment of a brown recluse bite. JAMA 1983; 250:648.
260. Phillips S, Kohn M, Baker D, Vander-Leest R, Gomez H, McKinney P, et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med 1995; 25:363-368.
261. Barrett S, Romine-Jenkins M, Fisher D. Dapsone or electric shock therapy of brown recluse spider bite envenomation? Ann Emerg Med 1994; 24:21-25.
262. Wesley R, Ballinger W, Close L, Lay A. Dapsone in the treatment of presumed brown recluse spider bite of the eyelid. Ophthalmic Surg 1985; 16:116-117, 120.
263. Cole H3, Wesley R, King LJ. Brown recluse spider envenomation of the eyelid: an animal model. Ophthal Plast Reconstr Surg 1995; 11:153-164.
264. Rees R, Altenbern D, Lynch J, King LJ. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg 1985; 202:659-663.
265. DeLozier J, Reaves L, King LJ, Rees R. Brown recluse spider bites of the upper extremity. South Med J 1988; 81:181-184.
266. Rees R, Campbell D, Rieger E, King L. The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med 1987; 16:945-949.
267. Wright S, Wrenn K, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med 1997; 30:28-32.
268. Binder L. Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989; 4:163-173.
269. Pennell T, Babu S, Meredith J. The management of snake and spider bites in the southeastern United States. Am Surg 1987; 53:198-204.
270. Futrell J. Loxoscelism. Am J Med Sci 1992; 304:261-267.
271. Benavides M, Moncada X. The treatment of cutaneous loxoscelism with dapsone. Rev Med Chil 1990; 118:1247-1250.
272. Gendron B. Loxosceles reclusa envenomation. Am J Emerg Med 1990; 8:51-54.
273. Holmes H. Stings and bites. Tips on coexisting comfortably with the insects. Postgrad Med 1990; 88:75-78.
274. Wong R, Hyghes S, Voorhees J. Spider bites. Arch Dermatol 1987; 123:98-105.
275. Wilson D, King LJ. Spiders and spider bites. Dermatol Clin 1990; 8:277-286.
276. Masters E. Images in clinical medicine. Loxoscelism. N Engl J Med 1998; 339:379.
277. Anderson P. Spider bites in the United States. Dermatol Clin 1997; 15:307-311.
278. Sneddon I, Wilkinson D. Subcorneal pustular dermatosis. Br J Dermatol 1956; 68:385-394.
279. Wolff K. Ein Beitrag zur Nosologie der subcornealen pustulosen Dermatose (Sneddon-Wilkinson). Arch Klin Exp Dermatol 1966; 224:248-267.
280. Sneddon I. Subcorneal pustular dermatosis. Int J Dermatol 1977; 16:640-644.
281. Sneddon I. Subkorneale pustuloese Dermatose. Hautarzt 1977; 28:63-66.
282. Sneddon I, Wilkinson D. Subcorneal pustular dermatosis. Br J Dermatol 1979; 100:61-68.
283. Wolff K. Subcorneal pustular dermatosis is not pustular psoriasis. Am J Dermatopathol 1981; 3:381-382.
284. Sanchez N, Perry H, Muller S, Winkelmann M. Subcorneal pustular dermatosis and pustular psoriasis. A clinicopathologic correlation. Arch Dermatol 1983; 119:715-721.
285. Lewis J. Urticarial vasculitis occurring in association with visceral malignancy. Acta Derm Venereol (Stockh) 1990; 70:345-347.
286. Aboobaker J, Greaves M. Urticarial vasculitis. Clin Exp Dermatol 1986; 11:436-444.
287. Hoffmann C, Richter W, Hiller C, Burg G. Urtikaria-Vaskulitis. Z Rheumatol 1986; 46:233-236.
288. Nishijima C, Hatta N, Inaoki M, Sakai H, Takehara K. Urticarial vasculitis in systemic lupus erythematosus: fair resonse to prednisolone/dapsone and persistent hypocomplementemia. Eur J Dermatol 1999; 9:54-56.
289. Eiser A, Singh P, Shanies H. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis -- a case report. Angiology 1997; 48:1019-1022.
290. Gonzalez-Quijada S, Lopez-Lazaro L, Reinares-Garcia L, Borregon-Carretero S, Sastre-Varela J, Estrada-Perez V. Gastrointestinal involvement and the response to dapsone in a case of the urticarial vasculitis syndrome. Med Clin Barc 1991; 97:706-708.
291. Wozel G, Thiele B. Urtikaria Vaskulitis und Sulfone, ein kasuistischer Beitrag. Z Hautkr 1987; 62:407-409.
292. Garcia-Bravo B, Camacho F. Urticarial vasculitis: a proposito de 12 casos. Med Cutan Ibero Lat Am 1986; 14:233-237.
293. Fortson J, Zone J, Hammond M, Groggel G. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. J Am Acad Dermatol 1976; 15:1137-1142.
294. Highet A. Urticarial vasculitis resembling systemic lupus erythematosus: efficacy of prednisone and dapsone combined. Br J Dermatol 1980; 102:358-360.
295. Nurnberg W, Grabbe J, Czarnetzki B. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol (Stockh) 1995; 75:54-56.
296. Matteson E. Interferon alpha 2a therapy for urticarial vasculitis with angioedema apparently following hepatitis A infection. J Rheumatol 1996; 23:382-384.
297. Asherson R, Buchanan N, Kenwright S, Fletcher C, Hughes G. The normocomplementemic urticarial vasculitis syndrome -- report of a case and response to colchicine. Clin Exp Dermatol 1991; 16:424-427.
298. Soter N. Cutaneous necrotizing venulitis. In: Fitzpatrick T, Eisen A, Wolff K, Freedberg I, Austen K, editors. Dermatology in General Medicine. 4th ed. New York: McGraw-Hill, Inc., 1993:1501-1510.
299. Ryan T. Cutaneous vasculitis. In: Rook A, Wilkinson D, Ebling F, editors. Textbook of Dermatology. 5th ed. Oxford: Blackwell Scientific Publications, 1992:1893-1961.
300. Habif T. Clinical Dermatology. St. Louis: The CV Mosby Company, 1990.
301. Ghersetich I, Jorizzo J, Lotti T. Working classification of vasculitis. Int Angiol 1995; 14:101-106.
302. Lotti T. The management of systemic complication of vasculitis. In: Panconesi E, editor. Dermatology in Europe. Oxford: Blackwell Sci Publ, 1991:330-332.
303. Lotti T, Ghersetich I, Comacchi C, Panconesi E. Purpuras and related conditions. J Eur Acad Dermatol Venereol 1996; 7:1-25.
304. Fredenberg M, Malkinson F. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987; 16:772-778.
305. Lotti T, Ghersetich I, Comacchi C, Jorizzo J. Cutaneous small-vessel vasculitis. J Am Acad Dermatol 1998; 39:667-687.
306. Valente R, Conn D. Current therapies for systemic vasculitis. Semin Neurol 1994; 14:380-386.
307. Smith JJ. Vasculitis. J Dermatol 1995; 22:812-822.
308. Weiss S. Tissue destruction by neutrophil. N Engl J Med 1989; 320:365-392.
309. Bozeman P, Learn D, Thomas E. Assay of the human leukocyte encymes myeloperoxidase and eosinophil peroxidase. J Immunol Methods 1990; 126:125-133.
310. Bozeman P, Learn D, Thomas E. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992; 44:553-563.
311. Stendahl O, Molin L, Lindroth M. Granulocyte-mediated release of histamine from mast cells. Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds. Int Arch Allergy Appl Immunol 1983; 70:277-284.
312. Kettle A, Gedye C, Winterbourn C. Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol 1993; 45:2003-2010.
313. Kettle A, Winterbourn C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991; 41:1485-1492.
314. Van Zyl J, Basson K, Kriegler A, van der Walt B. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties. Biochem Pharmacol 1991; 42:599-608.
315. Kazmierowski J, Ross J, Peizner D, Weupper K. Dermatitis herpetiformis: effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity. J Clin Immunol 1984; 4:55-64.
316. Barranco V. Inhibition of lysosomal enzymes by dapsone. Arch Dermatol 1974; 110:563-566.
317. Williams K, Capstick R, Lewis D, et al. Antiinflammatory actions of dapsone and its related biochemistry. J Pharm Pharmacol 1976; 28:555-558.
318. Niwa Y, Sakant T, Miyachi Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates -- in comparison with that of colchicine and various scavengers. Biochem Pharmacol 1984; 33:2355-2360.
319. Theron A, Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis 1985; 132:1049-1054.
320. Thuong-Nguyen V, Kadunce D, Hendrix J, Gammon W, Zone J. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993; 100:349-355.
321. Anderson R, Gatner E, van Rensburg C, Grabow G, Imkamp F, Kok S, et al. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother 1981; 19:495-503.
322. Harvath L, Yancey K, Katz S. Selective inhibition of neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986; 137:1305-1311.
323. Maloff B, Fox D, Bruin E, Di Meo T. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol 1988; 158:85-89.
324. Booth S, Moody C, Dahl M, Herron M, Nelson R. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98:135-140.
325. Debol S, Herron M, Nelson R. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transdaction. J Leukoc Biol 1997; 62:827-836.
326. Cucinell S, Israili Z, Dayton P. Microsomal N-oxidation of dapsone as a cause of methaemoglobin formation in human red cells. Am J Trop Med Hyg 1972; 21:322-311.
327. Coleman M, Pahal K, Gardiner J. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro. J Pharm Pharmacol 1996; 48:401-406.
328. Coleman M, Coleman N. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14:394-405.
329. Reilly T, Woster P, Svensson C. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions. J Pharmacol Exp Ther 1999; 288:951-959.
330. Tingle M, Mahmud R, Maggs J, Piemohamed M, Park B. Comaprison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 1997; 283:817-823.
331. Zone J. Dermatitis herpetiformis. Curr Prob Dermatol 1991; 3:3-41.
332. Galder B, Conrad M. Haemolysis by diphenylsulfones: Comparative effects of DDS and hydroxylamine-DDS. J Lab Clin Med 1973; 81:267-272.
333. Grossman S, Jollow D. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 1988; 244:118-125.
334. Uehleke H, Tabarelli S. N-hydroxylation of 4,4'-diaminodiphenyl-sulfone (dapsone) by liver microsomes and in dogs and humans. Naunyn-Schmeideberg's Arch Pharmacol 1988; 278:55-68.
335. Kramer P, Glader B, Li T. Mechanism of methaemoglobin formation by diphenylsulphones. Biochem Pharmacol 1972; 21:1265-1274.
336. Coleman M. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001; 162:53-60.
337. Hornsten P, Keisu M, Wilholm B. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126:919-922.
338. Kormann N, Vilhelmsen R, Stahl D. The dapsone syndrome. Arch Dermatol 1982; 118:531-532.
339. Prussick R, Shear N. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996; 35:346-349.
340. Kumar R, Kumar M, Thappa D. Dapsone syndrome -- a five year retrospective analysis. Indian J Lepr 1998; 70:271-276.
341. Jamrozik K. Dapsone syndrome occurring in two brothers. Lepr Rev 1986; 57:57-62.
342. Frey H, Gershon A, Borkowsky W, Bullock W. Fatal reactio to dapsone during treatment of leprosy. Ann Intern Med 1981; 94:777-779.
343. Chalasani P, Baffoe-Bonnie H, Jurado R. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J 1994; 87:1145-1146.
344. Reeve P, Ala J, Hall J. Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy. J Trop Med Hyg 1992; 95:266-270.
345. Mok C, Lau C. Dapsone syndrome in cutaneous lupus erythematosus. J Rheumatol 1996; 23:766-768.
346. Katoch K, Ramu G, Ramanathan U. Toxic epidermal necrolysis (Lyell syndrome). A case report. Lepr India 1983; 55:133-135.
347. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis 1994; 18:630-632.
348. Benedetti-Bardet C, Guy C, Boudigant O, Regnier-Zerbib A, Ollagnier M. Adverse effects of Disulone; results of the France pharmacovigilance inquiry. Regional Centers of Pharmacovigilance. Therapie 2001; 56:295-299.
349. Dhanapaul S. DDS-induced photosensitivity with reference to six case reports. Lepr Rev 1989; 60:147-150.
350. Daneshmed T. The neurotoxicity of dapsone. Adverse Drug React Acute Poisoning Rev 1984; 3:43-58.
351. Ahrens E, Meckler R, Callen J. Dapsone-induced peripheral neuropathy. Int J Dermatol 1986; 25:314-316.
352. Gutmann L, Martin J, Welton W. Dapsone motor neuropathy -- an axonal disease. Neurology 1976; 26:514-516.
353. Waldinger T, Siegle R, Wever W, Voorhees J. Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol 1984; 120:356-359.
354. Sirsat A, Lalitha V, Pandya S. Dapsone neuropathy -- report of three cases and pathologic features of a motor nerve. Int J Lepr Other Mycobact Dis 1987; 55:23-29.
355. Brasil M, Opromolla D, Marzliak M, Nogueira W. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. Int J Lepr Other Mycobact Dis 1996; 64:97-104.
356. Foster P, Swan C. Dapsone and fatal hypoalbuminaemia. Lancet 1981; 2:806-807.
357. Daneshmed T. Idiosyncratic dapsone induced manic depression. Br Med J 1989; 299:324.
358. Fine J, Katz S, Donaue M, et al. Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol 1983; 9:274-275.
359. Gawkrodger D. Manic depression induced by dapsone in a patient with dermatitis herpetiformis. Br Med J 1989; 299:860.
360. Gupta A, Eggo M, Uetrecht J, et al. Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51:56-67.
361. Maurus J. Hansen's disease in pregnancy. Obstet Gynecol 1978; 52:22-25.
362. Greenwood A, Armstrong J, Byass P, Snow R, Greenwood B. Malaria chemoprophylaxis, birth weight and child survival. Trans R Soc Trop Med Hyg 1992; 86:483-485.
363. Greenwood A, Menendez C, Todd J, Greenwood B. The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control women. Trans R Soc Trop Med Hyg 1994; 88:311-312.
364. Lopes V, Sarno E. Leprosy and pregnancy. Rev Assoc Med Bras 1994; 40:195-201.
365. Menendez C, Todd J, Alonso P, Lulat S, Francis N, Greenwood B. Malaria chemoprophylaxis, infection of the placenta and birth weight in Gambian primigravidae. J Trop Med Hyg 1994; 97:244-248.
366. Saunderson P, Gebre S, Desta K, Bypass P. The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics. Lepr Rev 2000; 71:273-284.
367. Edstein M, Veenedaal J, Newman K, Hyslop R. Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol 1986; 22:733-735.
368. Sanders S, Zone J, Foltz R, Tolman K, Rollins D. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 1982; 96:465-466.
© 2002 Dermatology Online Journal